<SEC-DOCUMENT>0001193125-24-259884.txt : 20241115
<SEC-HEADER>0001193125-24-259884.hdr.sgml : 20241115
<ACCEPTANCE-DATETIME>20241115164732
ACCESSION NUMBER:		0001193125-24-259884
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20241115
DATE AS OF CHANGE:		20241115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Disc Medicine, Inc.
		CENTRAL INDEX KEY:			0001816736
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851613057
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281359
		FILM NUMBER:		241468615

	BUSINESS ADDRESS:	
		STREET 1:		321 ARSENAL STREET, SUITE 101
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(617) 674-9274

	MAIL ADDRESS:	
		STREET 1:		321 ARSENAL STREET, SUITE 101
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemini Therapeutics, Inc. /DE
		DATE OF NAME CHANGE:	20210209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FS Development Corp.
		DATE OF NAME CHANGE:	20200702
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d912653d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR> Registration No 333-281359 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated
August&nbsp;8, 2024) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912653g96b12.jpg" ALT="LOGO" STYLE="width:4.50496in;height:0.701293in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Up to $200,000,000 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a
Controlled Equity Offering<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> Sales Agreement, or sales agreement, with Cantor Fitzgerald&nbsp;&amp; Co., or Cantor, relating to the sale of shares of our common stock offered by this prospectus.
In accordance with the terms of the sales agreement, pursuant to this prospectus supplement and the accompanying prospectus, we may offer and sell shares of our common stock having an aggregate gross sales price of up to $200.0&nbsp;million from
time to time through or to Cantor, acting as our sales agent or principal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Market under the symbol
&#147;IRON.&#148; On November&nbsp;14, 2024, the closing sale price of our common stock on The Nasdaq Global Market was $60.67 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of our
common stock, if any, under this prospectus supplement and the accompanying base prospectus will be made by any method permitted that is deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities
Act of 1933, as amended, or the Securities Act. Cantor is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal sales and trading
practices to sell on our behalf all of the shares of common stock requested to be sold by us, on mutually agreed terms between Cantor and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor will be entitled to compensation at a commission rate of up to 3.0% of the gross proceeds of any shares of common stock sold under the sales agreement.
In connection with the sale of our common stock on our behalf, Cantor will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cantor will be deemed to be underwriting commissions or discounts.
We have also agreed to provide indemnification and contribution to Cantor against certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended, or the Exchange Act. See &#147;Plan of
Distribution&#148; beginning on page S-13 for additional information regarding the compensation to be paid to Cantor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth
company&#148; and a &#147;smaller reporting company&#148; under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus supplement. Based on the aggregate
market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> as of June&nbsp;30, 2024, we expect to become a &#147;large accelerated filer&#148; and no longer qualify as an emerging growth company or a smaller
reporting company as of December&nbsp;31, 2024. See &#147;Prospectus Supplement Summary&#151;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See &#147;<A HREF="#suprom912653_4">Risk Factors</A>&#148; beginning on page <FONT
STYLE="white-space:nowrap">S-6</FONT> of this prospectus supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus supplement concerning factors you should consider before investing in our
common stock. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities,
or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying base prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912653g18b66.jpg" ALT="LOGO" STYLE="width:1.88276in;height:0.362361in;">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is November&nbsp;15, 2024. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom912653_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom912653_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-iv</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom912653_3">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom912653_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom912653_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom912653_6">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom912653_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-12</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom912653_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom912653_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom912653_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom912653_11">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom912653_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_2">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_3">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_5">ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_6">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_8">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_9">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_10">GENERAL DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_11">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_12">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_13">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_14">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_15">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_16">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_17">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom912653_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is part of an automatic shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the
Securities and Exchange Commission, or the SEC, as a &#147;well-known seasoned issuer&#148; as defined in Rule 405 of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document
is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of shares of our common stock having an aggregate offering price of up to $200,000,000 from time to time through or to Cantor, acting
as our sales agent, at prices and on terms to be determined by market conditions at the time of offering. The second part is the accompanying base prospectus, which provides more general information, some of which may not apply to this offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before buying any of the shares of common stock offered hereby, we urge you to read carefully this prospectus supplement and the accompanying base
prospectus, together with the information incorporated herein by reference as described below under the heading &#147;Incorporation of Certain Information by Reference.&#148; These documents contain important information that you should consider
when making your investment decision. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the accompanying base prospectus or the information contained in any document incorporated
by reference in this prospectus supplement that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided that if any statement in one of these
documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference in this prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier
statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and Cantor has not, authorized anyone to provide you with information other than the information that we have provided or
incorporated by reference in this prospectus supplement or the accompanying base prospectus and your reliance on any unauthorized information or representation is at your own risk. This prospectus supplement may be used only in jurisdictions where
offers and sales of these securities are permitted. You should assume that the information appearing in this prospectus supplement is accurate only as of the date of this prospectus supplement and that any information we have incorporated by
reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement, or any sale of our common stock. Our business, financial condition and results of operations may
have changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales
are permitted. The distribution of this prospectus supplement and the accompanying base prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. No action is being taken in any jurisdiction outside the
United States to permit a public offering of the securities or possession or distribution of this prospectus supplement or the accompanying base prospectus in that jurisdiction. Persons outside the United States who come into possession of this
prospectus supplement and the accompanying base prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and the distribution
of this prospectus supplement and the accompanying base prospectus outside the United States. This prospectus supplement and the accompanying base prospectus do not constitute, and may not be used in connection with, an offer to sell, or a
solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying base prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is
incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the
current state of our affairs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;29, 2022, we acquired Disc Medicine Opco, Inc. (formerly Disc Medicine, Inc.), or Private
Disc, pursuant to an agreement and plan of merger, or the Merger, and we changed our name to Disc Medicine, Inc. on December&nbsp;29, 2022. As used in this prospectus supplement, unless the context otherwise requires, references to &#147;Disc,&#148;
the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to (i)&nbsp;prior to the date of the Merger, Private Disc, and its wholly owned, consolidated subsidiaries, or either or all of them as the context may require, and
(ii)&nbsp;following the date of the Merger, Disc Medicine, Inc., and its wholly owned, consolidated subsidiaries, or either or all of them as the context may require. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom912653_2"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying base prospectus and the documents that we incorporate by reference contain &#147;forward-looking statements&#148;
within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. All statements, other than statements of historical facts, included in this prospectus supplement and the accompanying base prospectus, including
the documents that we incorporate by reference, regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking
statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148;
&#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying
words. These forward-looking statements include, among other things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, results, and cost of our research and development programs and our current and
future preclinical studies and clinical trials, including our planned APOLLO clinical trial of bitopertin, our ongoing Phase 1b/2 clinical trials of DISC-0974 and our ongoing Phase 1 clinical trial of DISC-3405, and including statements regarding
the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to efficiently discover and develop product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and the potential to successfully manufacture our drug substances and product candidates for
preclinical use, for clinical trials and on a larger scale for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations necessary to complete further development and commercialization
of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to use the U.S. Food and Drug Administration&#146;s, or FDA&#146;s, Accelerated Approval Program for
bitopertin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize our products, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, and strategic plans for our business and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations
or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future agreements with third parties in connection with the commercialization of product candidates and any other
approved product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing
cost; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of global economic and political developments on our business, including rising inflation and capital
market disruptions, the current conflicts between Russia and Ukraine and between Israel and Hamas, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts
as well as the value of our common stock and our ability to access capital markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of proceeds from this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;<I>Risk Factors</I>.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus supplement represent our views as of the date of this prospectus supplement. We
anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent
required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> provide estimates, projections and other information
concerning our industry, our business and the markets for our programs and product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual
events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and
research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any
misstatements regarding any third-party information presented in this prospectus supplement or the accompanying base prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and
uncertainties and are subject to change based on various factors. You should read this prospectus supplement, the accompanying base prospectus and any related free writing prospectus and the documents that we reference therein and have filed with
the SEC as exhibits thereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. These estimates involve numerous
assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed in our Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> which are incorporated into this prospectus supplement by reference, and the section of this prospectus supplement and the
accompanying base prospectus entitled &#147;Risk&nbsp;Factors.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom912653_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information about us and this offering and does not contain all of the information that you should consider before
investing in our common stock. You should read this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein and therein carefully, especially the discussion of the risks related to investing in our
common stock discussed under &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-7</FONT> of this prospectus supplement, and in our most recent annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and any
subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> we file after the date of this prospectus supplement, which are incorporated by reference in
this prospectus supplement, along with our consolidated financial statements and notes to those consolidated financial statements and the other information incorporated by reference in this prospectus supplement, before making an investment
decision. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. We have assembled a portfolio of clinical and preclinical product
candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Our current pipeline includes bitopertin for the treatment of
erythropoietic porphyrias, or EPs, including erythropoietic protoporphyria, or EPP, and <FONT STYLE="white-space:nowrap">X-linked</FONT> protoporphyria, or XLP, and Diamond-Blackfan Anemia, or DBA; DISC-0974 for the treatment of anemia of
myelofibrosis, or MF, and anemia of chronic kidney disease, or CKD; and DISC-3405 (formerly <FONT STYLE="white-space:nowrap">MWTX-003)</FONT> for the treatment of polycythemia vera, or PV, and other hematologic disorders. In addition, our
preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Our approach to product candidate development leverages well-understood molecular mechanisms that have been validated in humans. We
believe that each of our product candidates, if approved, has the potential to improve the lives of patients suffering from hematologic diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bitopertin is the lead product candidate in our heme biosynthesis modulation portfolio. Bitopertin was previously evaluated by F. <FONT
STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd and <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Inc., or collectively, Roche, in a comprehensive clinical program in over 4,000 individuals in other indications which demonstrated
the activity of bitopertin as a glycine transporter 1, or GlyT1, inhibitor and its effect on heme biosynthesis. We are initially developing bitopertin for the treatment of EPs, including EPP and XLP. In April 2024, we presented topline data from
AURORA, a Phase&nbsp;2, randomized, double-blind, placebo-controlled clinical trial of bitopertin in EPP patients conducted at sites in the United States. In June and December 2023, we presented interim data from BEACON, a Phase 2 open-label,
parallel-dose clinical trial of bitopertin in EPP and XLP patients conducted at sites in Australia. Additional analyses of the BEACON and AURORA trials were presented in June 2024 and we plan to share further analyses in December 2024. All
participants in AURORA and BEACON are eligible to participate in HELIOS, an ongoing open-label, long-term extension clinical trial of bitopertin in EPP and XLP. We are also planning APOLLO, a randomized, double-blind, placebo-controlled clinical
trial of bitopertin in EPP and XLP patients. As a result of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting with the U.S. Food&nbsp;&amp; Drug Administration, or the FDA, we agreed with the
FDA on all proposed attributes of the APOLLO trial, which we plan to initiate by <FONT STYLE="white-space:nowrap">mid-2025.</FONT> In addition, the FDA agreed with the potential for reduction of protoporphyrin IX, or PPIX, to serve as a surrogate
endpoint to support a potential accelerated approval. Under the FDA&#146;s Accelerated Approval Program, we would have the potential to submit a New Drug Application, or NDA, for bitopertin in EPP and XLP based on our existing data and, subject to
further discussion with the FDA, APOLLO would serve as a confirmatory trial. We will be meeting with the FDA to finalize the details of APOLLO and plan to provide an update in the first quarter of 2025 on this discussion as well as timing for a
potential NDA filing under an accelerated pathway. We have also entered into a collaborative research and development agreement with the National Institutes of Health, or NIH, to conduct an <FONT STYLE="white-space:nowrap">NIH-sponsored</FONT>
clinical trial of bitopertin in DBA. The FDA authorized the clinical trial to proceed and the trial began in July 2023. We are planning additional trials of bitopertin in other indications. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DISC-0974 is the lead product candidate in our iron homeostasis portfolio and was <FONT
STYLE="white-space:nowrap">in-licensed</FONT> from AbbVie Deutschland GmbH&nbsp;&amp; Co. KG, or AbbVie. DISC-0974 is designed to suppress hepcidin production and increase serum iron levels. We submitted an Investigational New Drug application, or
IND, to the FDA for DISC-0974 in June 2021, received clearance in July 2021, and participants completed a Phase 1 clinical trial in healthy volunteers in the U.S. in June 2022 with results showing an acceptable tolerability profile and evidence of
target engagement, iron mobilization and augmented erythropoiesis. We initiated a Phase 1b/2 clinical trial in June 2022 in patients with anemia of MF, and initiated a separate Phase 1b/2 clinical trial in February 2023 in patients with <FONT
STYLE="white-space:nowrap">non-dialysis</FONT> dependent CKD and anemia. We presented interim data from both of these trials in December 2023 as well as additional interim data for anemia of MF in June 2024 and
<FONT STYLE="white-space:nowrap">non-dialysis</FONT> dependent CKD and anemia in October 2024, which additional interim data included safety and changes in hepcidin, iron, and hemoglobin levels for additional patients, as well as longer <FONT
STYLE="white-space:nowrap">follow-up.</FONT> We anticipate presenting additional analyses of the Phase 1b study in anemia of MF in December 2024. In addition, we are developing a preclinical anti-hemojuvelin, or HJV, monoclonal antibody, DISC-0998,
which also targets hepcidin suppression and was <FONT STYLE="white-space:nowrap">in-licensed</FONT> from AbbVie. DISC-0998 is designed to increase serum iron levels and has an extended serum half-life as compared to DISC-0974. We believe this
profile may be desirable in certain subsets of patients with anemia associated with inflammatory diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lastly, we are developing DISC-3405, a
monoclonal antibody against Transmembrane Serine Protease 6, or TMPRSS6, that we licensed from Mabwell Therapeutics, Inc., or Mabwell. DISC-3405 is part of our iron homeostasis portfolio and is designed to induce hepcidin production and reduce serum
iron levels. An IND for DISC-3405 was cleared by the FDA, and a Phase 1 clinical trial in healthy adult volunteers was initiated in October 2023. Interim data was presented from the single-ascending dose, or SAD, portion of the Phase 1 clinical
trial of DISC-3405 in healthy volunteers in June 2024. We anticipate presenting data from the multiple-ascending dose, or MAD, portion of the Phase 1 healthy volunteer study of DISC-3405 in December 2024. We expect to develop DISC-3405 for the
treatment of PV and other hematologic disorders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disc Medicine, Inc. was originally incorporated under the laws of the state of Delaware in October 2017, and changed its name to Disc Medicine Opco, Inc., or
Disc Opco, in December 2022. On December&nbsp;29, 2022, we completed our business combination with Gemini Therapeutics, Inc., or Gemini, in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of August&nbsp;9,
2022, or the Merger Agreement, by and among Gemini, us and Gemstone Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gemini, or Merger Sub, pursuant to which, among other matters, Merger Sub merged with and into Disc Opco,
with Disc Opco continuing as a wholly owned subsidiary of us and the surviving corporation of the merger, or the Merger. In connection with the closing of the Merger, Gemini changed its name to Disc Medicine, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 321 Arsenal Street, Suite 101, Watertown, MA 02472, and our telephone number is (617) <FONT
STYLE="white-space:nowrap">674-9274.</FONT> We maintain an Internet website at the following address: www.discmedicine.com. We do not incorporate the information on or accessible through our website into this prospectus supplement, and you should
not consider any information on, or that can be accessed through, our website as part of this prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging
Growth Company and a Smaller Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups
Act of 2012, as amended, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to only disclose two years of audited financial statements in addition to any required unaudited
interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any
golden parachute arrangements not previously approved; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until the end of the fiscal year following the fifth anniversary of our initial
public offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross
revenue of $1.235&nbsp;billion or more; (ii)&nbsp;December 31, 2025; (iii) the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the last day of the fiscal year in which we
are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th. We
may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus supplement. Accordingly, the information contained herein may be different from the information you
receive from other public companies in which you hold stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may
continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination
that our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than $250&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenues are less than $100&nbsp;million during the
most recently completed fiscal year and our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than $700&nbsp;million measured on the last business day of our second fiscal quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the aggregate market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> as of June&nbsp;30, 2024, we expect
that will become a &#147;large accelerated filer&#148; and no longer qualify as an emerging growth company or a smaller reporting company as of December&nbsp;31, 2024. Accordingly, beginning with our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024, we may no longer be permitted to take advantage of the reduced reporting requirements applicable to an emerging growth company or a smaller reporting company and will
be required to adhere to, among other things, the auditor attestation report on our system of internal controls over financial reporting otherwise required by Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock offered by us</B> </P></TD>
<TD>Shares of our common stock having an aggregate offering price of up to $200,000,000. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock to</B> <B>be outstanding after this offering</B> </P></TD>
<TD>Up to 33,044,676&nbsp;shares of our common stock, assuming sales of 3,296,522&nbsp;shares of our common stock in this offering at an offering price of $60.67 per share, which was the last reported sale price of our common stock on The Nasdaq
Global Market on November&nbsp;14, 2024. The actual number of shares of common stock issued will vary depending on the sales price under this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Plan of Distribution</B> </P></TD>
<TD>&#147;At the market offering&#148; that may be made from time to time on The Nasdaq Global Market or such other national securities exchange on which our common stock is then listed, through or to our sales agent, Cantor. See the section
entitled &#147;Plan of Distribution&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-13</FONT> of this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds</B> </P></TD>
<TD>We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund research and clinical development of, and pre-commercialization and, if approved, commercialization activities for, our
current and future product candidates, and the remainder for working capital and other general corporate purposes. We may also use a portion of the net proceeds to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in
complementary businesses or technologies to continue to build our pipeline, research and development capabilities and our intellectual property position. See &#147;Use of Proceeds&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-9</FONT> of
this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors</B> </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus supplement beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-7</FONT> and the other information included in, or incorporated by reference into, this prospectus
supplement and the accompanying base prospectus for a discussion of factors to consider before deciding to purchase shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market symbol</B> </P></TD>
<TD>IRON </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All information in this prospectus supplement related to the number of shares of our common stock to be outstanding immediately
after this offering is based on 29,748,154 shares of our common stock outstanding as of September&nbsp;30, 2024. The number of shares of our common stock outstanding as of September&nbsp;30, 2024 as used throughout this prospectus supplement, unless
otherwise indicated, excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,972,432 shares of common stock issuable upon the exercise of stock options outstanding as of September&nbsp;30,
2024, at a weighted average exercise price of $25.29 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">73,935 shares of common stock issuable upon the exercise of stock options granted subsequent to
September&nbsp;30, 2024, at a weighted average exercise price of $47.65 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">429,522 shares of common stock issuable upon the vesting of restricted stock awards outstanding as of
September&nbsp;30, 2024; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">49,286 shares of common stock issuable upon the vesting of restricted stock awards granted subsequent to
September&nbsp;30, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">204,081 shares of common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants outstanding as of September&nbsp;30, 2024, at an exercise price of $0.0001 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,634,822 shares of common stock available for future issuance under our Amended and Restated 2021 Stock Option
and Incentive Plan as of September&nbsp;30, 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">254,926 shares of common stock available for future issuance under our Amended and Restated 2021 Employee Stock
Purchase Plan as of September&nbsp;30, 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise stated, all information contained in this prospectus supplement
(i)&nbsp;assumes no exercise of stock options after September&nbsp;30, 2024 and (ii)&nbsp;reflects an assumed public offering price of $60.67, which was the last reported sale price of our common stock on The Nasdaq Global Market on
November&nbsp;14, 2024. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom912653_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock, you should carefully consider the risks and
uncertainties described below, in the accompanying base prospectus, and in our most recently filed Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and other
filings we make with the SEC from time to time, which are incorporated by reference herein in their entirety, together with all other information contained in this prospectus supplement and in our filings with the SEC that we have incorporated by
reference in this prospectus supplement. If any of the following risks actually occurs, our business, financial condition or results of operations could be adversely affected, which, in turn, could have a negative impact on the price of our common
stock. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional
Risks Related To Our Common Stock And This Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of common stock in this offering, you may suffer immediate and
substantial dilution of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The price per share of our common stock in this offering may exceed the net tangible book value per share
of our common stock outstanding prior to this offering. Therefore, if you purchase shares of our common stock in this offering, you may pay a price per share that substantially exceeds our net tangible book value per share after this offering. To
the extent shares are issued under outstanding options at exercise prices lower than the price of our common stock in this offering, you will incur further dilution. Assuming that an aggregate of 3,296,522 shares of our common stock are sold at a
price of $60.67 per share, the last reported sale price of our common stock on The Nasdaq Global Market on November&nbsp;14, 2024, for aggregate net proceeds to us of $195.3&nbsp;million, after deducting commissions and estimated aggregate offering
expenses payable by us, investors in this offering would experience immediate dilution of $40.60&nbsp;per share, representing the difference between our as adjusted net tangible book value per share as of September&nbsp;30, 2024, after giving effect
to this offering and the assumed offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This dilution is due to the substantially lower price paid by some of our investors who purchased shares
prior to this offering as compared to the price offered to the public in this offering and the exercise of stock options granted to our employees, directors and consultants. See the section entitled &#147;Dilution&#148; below for a more detailed
illustration of the dilution you would incur if you participate in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this
offering and may use them in ways that you and other stockholders may not approve. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently expect to use the net proceeds of this offering to
fund research and clinical development of current or additional product candidates, and the remainder for working capital and other general corporate purposes. We may also use a portion of the net proceeds to
<FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in complementary businesses or technologies to continue to build our pipeline, research and development capabilities and our intellectual property position. Because of the number
and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management will have broad discretion in the application of the net
proceeds from this offering and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Our management might not spend the net proceeds in ways that improve our results
of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to
decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. See &#147;Use of Proceeds.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our
common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors in this offering, and
investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common
stock, in future transactions may be higher or lower than the price per share paid by investors in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales or issuances of our
common stock in the public markets, or the perception of such sales, could depress the trading price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale of a
substantial number of shares of our common stock or other securities convertible into or exchangeable for our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock and
impair our ability to raise capital through the sale of additional equity securities. We may sell large quantities of our common stock at any time pursuant to this prospectus supplement or in one or more separate offerings. We cannot predict the
effect that future sales of common stock or other equity-related securities would have on the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The actual number
of shares we will issue and gross proceeds resulting from those sales, at any one time or in total, is uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain limitations
in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to Cantor at any time throughout the term of the sales agreement. The number of shares that are sold by Cantor after delivering a
placement notice will fluctuate based on the market price of our common stock during the sales period and limits we set with Cantor in any instruction to sell shares, and the demand for our common stock during the sales period. Because the price per
share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares or the gross proceeds to be raised in connection with those sales, if
any, that will be ultimately issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The common stock offered hereby will be sold in &#147;at the market offerings,&#148; and investors who buy
shares at different times will likely pay different prices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors who purchase shares in this offering at different times will likely pay
different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices and numbers of shares sold, and there is no minimum or maximum sales price.
Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices they paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unstable
market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As widely reported,
global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth,
increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be
adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or
equity financing more difficult, more costly, and more dilutive. Furthermore, our stock price may decline due in part to the volatility of the stock market and the general economic downturn. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to secure any necessary financing in a timely manner and on favorable terms could have a material
adverse effect on our growth strategy, financial performance and stock price and could require us to delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential <FONT
STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly
affect our ability to attain our operating goals on schedule and on budget. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom912653_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the sales agreement, we may issue and sell shares of our common stock having aggregate sales proceeds of up to $200,000,000 (before deducting
sales agent commissions and expenses) from time to time under this prospectus supplement and the accompanying base prospectus. The amount of the net proceeds to us from this offering will depend upon the number of shares of our common stock sold and
the price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with Cantor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund research and clinical
development of, and pre-commercialization and, if approved, commercialization activities for, our current and future product candidates, and the remainder for working capital and other general corporate purposes. We may also use a portion of the net
proceeds to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in complementary businesses or technologies to continue to build our pipeline, research and development capabilities and our intellectual property position. We have
not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the
future as our plans and business conditions evolve. We have not determined the amounts we plan to spend on any of the areas listed above or the timing of these expenditures. The amounts and timing of our actual expenditures may vary significantly
depending on numerous factors, including the actual net proceeds from this offering (which will depend on the market price of our common stock during the sales period, any limits we may set with Cantor in any applicable placement notice and the
demand for our common stock), the progress of our development, the status of and results from clinical trials and collaborations that we may enter into with third parties for our product candidates and any unforeseen cash needs, including the
factors described under &#147;Risk Factors&#148; in this prospectus supplement and the accompanying base prospectus and in the documents incorporated by reference herein. We may find it necessary or advisable to use the net proceeds from this
offering for other purposes. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do
not expect that the net proceeds from this offering, together with our existing cash and cash equivalents, will be sufficient to enable us to fund the completion of development of any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including
short-term, investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom912653_6"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering price per
share and the as adjusted net tangible book value per share of our common stock after giving effect to this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2024, we
had a net tangible book value of approximately $468.0&nbsp;million, or $15.73 per share of our common stock, based upon 29,748,154 shares of our common stock outstanding as of that date. Net tangible book value per share is equal to our total
tangible assets, less total liabilities, divided by the number of outstanding shares of our common stock. Dilution in net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common
stock in this offering and the as adjusted net tangible book value per share of our common stock immediately after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to
the sale of our common stock pursuant to this prospectus supplement in the aggregate amount of $200,000,000 at an assumed offering price of $60.67 per share, the last reported sale price of our common stock on The Nasdaq Global Market on
November&nbsp;14, 2024, and after deducting sales agent commissions and estimated aggregate offering expenses payable by us, our as adjusted net tangible book value as of September&nbsp;30, 2024 would have been $663.3 million, or $20.07 per share of
common stock. This represents an immediate increase in the net tangible book value of $4.34 per share to our existing stockholders and an immediate dilution in net tangible book value of $40.60 per share of common stock to investors in this offering
based on the assumed offering price. Dilution per share to investors is determined by subtracting as adjusted net tangible book value per share after this offering from the assumed public offering price per share paid by investors. The following
table illustrates this per share dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of September&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to sale of shares of common stock in
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share as of September&nbsp;30, 2024, after this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in net tangible book value per share to investors purchasing shares in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above assumes for illustrative purposes that an aggregate of 3,296,522&nbsp;shares of our common stock are sold
pursuant to this prospectus supplement at a price of $60.67&nbsp;per share, the last reported sale price of our common stock on The Nasdaq Global Market on November 14, 2024, for aggregate gross proceeds of $200,000,000. The shares sold in this
offering, if any, will be sold from time to time at various prices. An increase of $1.00&nbsp;per&nbsp;share in the price at which the shares are sold from the assumed offering price to $61.67&nbsp;per share, assuming all of our common stock in the
aggregate amount of $200,000,000 is sold at that price, would result in an as adjusted net tangible book value per share after the offering of $20.10 per share and would increase the dilution in net tangible book value per share to investors in this
offering to $41.57 per share, after deducting sales agent commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00&nbsp;per share in the price at which the shares are sold from the assumed offering price to
$59.67&nbsp;per share, assuming all of our common stock in the aggregate amount of $200,000,000 is sold at that price, would result in an as adjusted net tangible book value per share after the offering of $20.04 per share and would decrease the
dilution in net tangible book value per share to investors in this offering to $39.63 per share, after deducting sales agent commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes
only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 29,748,154 shares of our common stock outstanding as of
September&nbsp;30, 2024 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,972,432 shares of common stock issuable upon the exercise of stock options outstanding as of September&nbsp;30,
2024, at a weighted average exercise price of $25.29&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">73,935 shares of common stock issuable upon the exercise of stock options granted subsequent to
September&nbsp;30, 2024, at a weighted average exercise price of $47.65 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">429,522 shares of common stock issuable upon the vesting of restricted stock awards outstanding as of
September&nbsp;30, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">49,286 shares of common stock issuable upon the vesting of restricted stock awards granted subsequent to
September&nbsp;30, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">204,081 shares of common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants outstanding as of September&nbsp;30, 2024, at an exercise price of $0.0001 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,634,822 shares of common stock available for future issuance under our Amended and Restated 2021 Stock Option
and Incentive Plan as of September&nbsp;30, 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">254,926 shares of common stock available for future issuance under our Amended and Restated 2021 Employee Stock
Purchase Plan as of September&nbsp;30, 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that options outstanding as of September&nbsp;30, 2024 have been or may be
exercised or settle, as applicable, or other shares are issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic
considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could
result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom912653_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently plan to retain all of our future earnings, if any, to finance the operation,
development and growth of our business. We do not expect to pay any cash dividends on our common stock in the foreseeable future. Payment of future dividends, if any, will be at the discretion of our board of directors and will depend on our
financial condition, results of operations, capital requirements, restrictions contained in current or future financing instruments, provisions of applicable law and other factors the board deems relevant. In addition, the terms of our loan and
security agreement with Hercules Capital, Inc. restrict, and any future debt arrangements may restrict, our ability to pay dividends on our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom912653_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into the sales agreement with Cantor. Pursuant to this prospectus supplement and the accompanying prospectus, we may offer and sell shares of
our common stock having an aggregate gross sales price of up to $200,000,000 from time to time to or through Cantor, acting as sales agent or principal. A copy of the sales agreement was filed as Exhibit&nbsp;1.1 to a Current Report on Form&nbsp;8-K
filed with the SEC under the Exchange Act on November&nbsp;15, 2024, which is incorporated by reference in this prospectus supplement and the accompanying base prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon delivery of a placement notice and subject to the terms and conditions of the sales agreement, Cantor may sell shares of our common stock by any method
permitted by law deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act. We may instruct Cantor not to sell common stock if the sales cannot be effected at or above the price or in excess
of a specified number of shares designated by us from time to time. We or Cantor may suspend the offering of common stock upon notice and subject to other conditions set forth in the sales agreement. We and Cantor may also agree to sell shares to
Cantor as principal at a price agreed upon by the parties at each relevant time shares are sold pursuant to the sales agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay Cantor
commissions, in cash, for its service in acting as agent in the sale of our common stock. Cantor will be entitled to compensation at a commission rate of up to 3.0% of the sales price per share sold under the sales agreement. Because there is no
minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse Cantor for certain specified
expenses, including the fees and disbursements of their legal counsel in an amount not to exceed $75,000 in connection with the execution of the sales agreement and certain ongoing expenses. We estimate that the total expenses for the offering,
excluding compensation and reimbursements payable to Cantor under the terms of the sales agreement, will be approximately $190,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Settlement for sales
of shares of our common stock will occur on the trading day following the date on which any sales are made, in return for payment of the net proceeds to us. Sales of our common stock as contemplated in this prospectus supplement will be settled
through the facilities of The Depository Trust Company or by such other means as we and Cantor may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor will use its commercially reasonable efforts, consistent with its sales and trading practices, to solicit offers to purchase the common stock under the
terms and subject to the conditions set forth in the sales agreement. In connection with the sale of the common stock on our behalf, Cantor will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation
of Cantor will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to Cantor against certain civil liabilities, including liabilities under the Securities Act and the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering of shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus will terminate upon the termination of the
sales agreement as permitted therein. We and Cantor may each terminate the sales agreement at any time upon ten days&#146; prior notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor and its
affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M,
Cantor will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
prospectus supplement and the accompanying prospectus may be made available in electronic format on a website maintained by Cantor, and Cantor may distribute this prospectus supplement and the accompanying prospectus electronically. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom912653_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Cantor
Fitzgerald&nbsp;&amp; Co. is being represented in connection with this offering by Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom912653_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Disc Medicine, Inc. appearing in Disc Medicine, Inc.&#146;s Annual Report
<FONT STYLE="white-space:nowrap">(Form&nbsp;10-K)&nbsp;for</FONT> the years ended December&nbsp;31, 2023 and 2022, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon,
included therein, and incorporated herein by reference. Such consolidated financial statements are, and audited financial statements to be included in subsequently filed documents will be, incorporated herein in reliance upon the reports of
Ernst&nbsp;&amp; Young LLP pertaining to such financial statements (to the extent covered by consents filed with the Securities and Exchange Commission) given on the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom912653_11"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the
Internet at the SEC&#146;s website at www.sec.gov and on our investor website at www.discmedicine.com. Our website is not a part of this prospectus supplement and is not incorporated by reference in this prospectus supplement or the accompanying
base prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is part of a registration statement that we have filed with the SEC. Certain information in the registration
statement has been omitted from this prospectus supplement in accordance with the rules of the SEC. For more detail about us and any securities that may be offered by this prospectus supplement, you may examine the registration statement of which
this prospectus supplement forms a part, including its exhibits and schedules. Statements contained in this prospectus supplement and the accompanying base prospectus as to the contents of any contract or other document are not necessarily complete,
and in each instance we refer you to the copy of the contract or document filed as an exhibit to the registration statement, each such statement being qualified in all respects by such reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom912653_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference in this prospectus supplement much of the information we file with the SEC, which means that we can disclose
important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus supplement and the accompanying base prospectus is considered to be part of this prospectus
supplement. Because we are incorporating by reference future filings with the SEC, this prospectus supplement is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus
supplement. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus supplement or in any document previously incorporated by reference have been modified or
superseded. This prospectus supplement incorporates by reference the documents listed below and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any future report or
document that is not deemed filed under such provisions, between the date of the initial registration statement of which this prospectus supplement forms a part and the effectiveness of the registration statement and following the effectiveness of
the registration statement until we terminate or sell all of the securities offered hereby: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended&nbsp;December 31,
2023 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000095017024034432/iron-20231231.htm">March&nbsp;21, 2024</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2024, June&nbsp;30, 2024 and September&nbsp;30, 2024, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000095017024056304/iron-20240331.htm">May&nbsp;
9, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000095017024093357/iron-20240630.htm">August&nbsp;
8, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000095017024124650/iron-20240930.htm">November&nbsp;12, 2024</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000119312524025951/d758257d8k.htm">February&nbsp;7,
 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000119312524084937/d815786d8k.htm">April&nbsp;
2, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000119312524161170/d826950d8k.htm">June&nbsp;
14, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000119312524161587/d828009d8k.htm">June 14, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000119312524161603/d829753d8k.htm">June&nbsp;14,
 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000095017024117318/iron-20241025.htm">October&nbsp;
25, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000095017024120292/iron-20241104.htm">November&nbsp;
4, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000095017024123718/iron-20241106.htm">November&nbsp;
8, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001816736/000119312524259855/d913169d8k.htm">November&nbsp;15, 2024</A> (in each case, excluding information furnished pursuant to Item 7.01); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our Registration Statement on Form <FONT
STYLE="white-space:nowrap">8-A</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1816736/000121390020021145/ea125295-8a12b_fsdevelop.htm">August&nbsp;10, 2020</A>, and as set forth by the description of the
Registrant&#146;s common stock set forth in <A HREF="http://www.sec.gov/Archives/edgar/data/1816736/000095017022003288/gmtx-ex4_4.htm">Exhibit 4.4</A> to the Registrant&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for
the year ended December&nbsp;31, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000095017022003288/gmtx-20211231.htm">March&nbsp;10, 2022</A>, and as further supplemented by
the description of the Registrant&#146;s common stock set forth in the Registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4/A,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1816736/000114036122043943/ny20005172x8_s4a.htm">December&nbsp;1,
 2022</A>, including any amendments or reports filed for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a copy of these
filings, at no cost, by writing or telephoning us at the following address or telephone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Disc Medicine, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">321 Arsenal Street, Suite 101 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Watertown, MA 02472 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor
Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(617) <FONT STYLE="white-space:nowrap">674-9274</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may also access these documents, free of charge on the SEC&#146;s website at<I> www.sec.gov</I> or on our website at<I> www.discmedicine.com</I>.
Information contained on our website is not incorporated by reference into this prospectus supplement or the accompanying base prospectus, and you should not consider any information on, or that can be accessed from, our website as part of this
prospectus supplement or the accompanying base prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, unless specifically stated to the contrary, information that we
furnish (and that is not deemed &#147;filed&#148; with the SEC) under Items 2.02 and 7.01 of any Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> including the related exhibits under Item 9.01, is not incorporated by reference
into this prospectus supplement or the accompanying base prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Rule 412 of the Securities Act, any statement contained in a document incorporated by
reference herein shall be deemed modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such
statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912653g03g03.jpg" ALT="LOGO" STYLE="width:4.55208in;height:0.71875in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt
Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may offer
and sell, in one or more series or classes, our Common Stock, Preferred Stock, Debt Securities, Warrants or Units, in each case in one or more issuances and at prices and on terms that we will determine at the time of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus describes the general manner in which any of these securities may be offered using this prospectus. We will specify in an accompanying
prospectus supplement the terms of the securities offered and other details regarding the offering thereof. The supplement may also add, update or change information contained in this prospectus with respect to that offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Market under the symbol &#147;IRON.&#148; On August&nbsp;7, 2024, the closing price of our common stock, as
reported on The Nasdaq Global Market, was $41.27 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our securities involves risks. You should review carefully the risks and uncertainties described under the heading &#147;</B><I><A HREF="#tx912653_6"></A></I><B><I><A HREF="#tx912653_6">Risk
Factors</A></I></B><I><A HREF="#tx912653_6"></A></I><B>&#148; on page 10 of this prospectus and under any similar heading in the documents that are incorporated by reference into this prospectus, as well as &#147;</B><B><I>Special Note Regarding
Forward-Looking Statements</I></B><B>&#148; on page 4 of this prospectus. You should read the entire prospectus and any applicable prospectus supplement carefully before you make your investment decision. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities covered by this prospectus may be sold directly by us to investors, through agents designated by us from time to time or through underwriters
or dealers at prices and on terms to be determined at the time of offering. We will include in an applicable prospectus supplement the names of any underwriters or agents and any applicable commissions or discounts. Additional information on the
methods of sale appears under &#147;<I>Plan of Distribution</I>&#148; in this prospectus. We will also describe in an applicable prospectus supplement the way(s) in which we expect to use the net proceeds we receive from any sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to offer or sell any
securities unless accompanied by a prospectus supplement. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is August&nbsp;8, 2024. </B></P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Table of Contents </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_2">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_3">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_5">ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_6">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_8">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_9">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_10">GENERAL DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_11">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_12">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_13">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_14">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_15">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_16">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912653_17">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained or incorporated by reference in this prospectus and in an applicable
prospectus supplement to this prospectus. We have not authorized any other person to provide you with different or additional information. If anyone provides you with different, additional or inconsistent information, you should not rely on it. We
do not take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are not making an offer to sell these securities or soliciting any offer to buy these securities in any
jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus, any applicable prospectus supplement or any free writing prospectus we authorize to be delivered to you is accurate only as
of the date of that document or any other date set forth in that document. Additionally, any information we have incorporated by reference in this prospectus or in any applicable prospectus supplement is accurate only as of the date of the document
incorporated by reference or other date set forth in that document, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any sale of securities. Our business, financial condition, results of operations, cash
flow and prospects may have changed since that date. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>On December&nbsp;29, 2022, we acquired Disc Medicine Opco, Inc. (formerly Disc Medicine,
Inc.), or Private Disc, pursuant to an agreement and plan of merger, or the Merger, and we changed our name to Disc Medicine, Inc. on December&nbsp;29, 2022. As used in this prospectus, unless the context otherwise requires, references to
&#147;Disc,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to (i)&nbsp;prior to the date of the Merger, Private Disc, and its wholly owned, consolidated subsidiaries, or either or all of them as the context
may require, and (ii)&nbsp;following the date of the Merger, Disc Medicine, Inc., and its wholly owned, consolidated subsidiaries, or either or all of them as the context may require. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of an automatic shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we have filed with the
Securities and Exchange Commission, or the SEC, as a &#147;well-known seasoned issuer&#148; as defined in Rule 405 of the Securities Act of 1933, as amended, or the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under this process, we may sell the securities described in this prospectus in one or more offerings. This prospectus describes the general manner in which we
may offer the securities described in this prospectus. Each time we sell securities pursuant to this registration statement, we will provide a prospectus supplement that will contain specific information about the offering and the securities
offered, and may also add, update or change information contained in this prospectus. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. If there is
any inconsistency between information in this prospectus and any accompanying prospectus supplement or free writing prospectus, you should rely on the information in the most recent applicable prospectus supplement or free writing prospectus and
documents incorporated by reference herein and therein. This prospectus may not be used to offer to sell, solicit an offer to buy or consummate a sale of our securities unless it is accompanied by a prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, together with any accompanying prospectus supplement together with any additional information incorporated by reference, contains important
information you should know before investing in our securities, including important information about us and the securities being offered. You should carefully read both documents, as well as the additional information contained in the documents
described under &#147;<I>Where You Can Find More Information&#148; </I>and &#147;<I>Incorporation of Certain Information by Reference</I>&#148; in both this prospectus and the applicable prospectus supplement, and in particular the annual, quarterly
and current reports and other documents we file with the SEC. Neither this prospectus nor any accompanying prospectus supplement is an offer to sell these securities or is soliciting an offer to buy these securities in any jurisdiction where the
offer or sale is not permitted. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_2"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act of 1933, as amended, or the
Securities Act, with respect to the securities offered by this prospectus and any applicable prospectus supplement. This prospectus and the applicable prospectus supplement do not contain all of the information set forth in the registration
statement and its exhibits and schedules in accordance with SEC rules and regulations. For further information with respect to us and the securities being offered by this prospectus and the applicable prospectus supplement, you should read the
registration statement, including its exhibits and schedules. Statements contained in this prospectus and the applicable prospectus supplement, including documents that we have incorporated by reference, as to the contents of any contract or other
document referred to are not necessarily complete, and, with respect to any contract or other document filed as an exhibit to the registration statement or any other such document, each such statement is qualified in all respects by reference to the
corresponding exhibit. You should review the complete contract or other document to evaluate these statements. You may obtain copies of the registration statement and its exhibits via the SEC&#146;s EDGAR database or our website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other documents with the SEC under the U.S. Securities Exchange Act of 1934, as amended,
or the Exchange Act. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers, including us, that file electronically with the SEC. You may obtain documents that we file with the SEC
at <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also make these documents available on our website at <I>www.discmedicine.com</I>. Our website and the information contained or
connected to our website is not incorporated by reference in this prospectus or any prospectus supplement, and you should not consider it part of this prospectus or any prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_3"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEC rules permit us to incorporate information by reference in this prospectus and any applicable prospectus supplement. This means that we can disclose
important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus and any applicable prospectus supplement, except for information
superseded by information contained in this prospectus or the applicable prospectus supplement itself or in any subsequently filed incorporated document. This prospectus and any applicable prospectus supplement incorporate by reference the documents
set forth below that we have previously filed with the SEC, other than information in such documents that is deemed to be furnished and not filed. These documents contain important information about us and our business and financial condition. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31,
2023, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001816736/000095017024034432/iron-20231231.htm">March<U></U>&nbsp;21, 2024</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Reports <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-Q&nbsp;for&nbsp;the</FONT> quarters ended
March&nbsp;31, 2024 and June&nbsp;30, 2024, filed with the SEC on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000095017024056304/iron-20240331.htm">May&nbsp;
9, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000095017024093357/iron-20240630.htm">August&nbsp;8, 2024</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001816736/000119312524025951/d758257d8k.htm">February&nbsp;7,
 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001816736/000119312524084937/d815786d8k.htm">April&nbsp;
2, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001816736/000119312524161170/d826950d8k.htm">June<U></U>&nbsp;
14, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001816736/000119312524161587/d828009d8k.htm">June&nbsp;
14, 2024</A> (in each case, excluding information furnished pursuant to Item 7.01) and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001816736/000119312524161603/d829753d8k.htm">June&nbsp;14, 2024</A> ; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our Registration Statement on Form <FONT
STYLE="white-space:nowrap">8-A</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1816736/000121390020021145/ea125295-8a12b_fsdevelop.htm">August&nbsp;10, 2020</A>, and as set forth by the description of the
Registrant&#146;s common stock set forth in <A HREF="http://www.sec.gov/Archives/edgar/data/1816736/000095017022003288/gmtx-ex4_4.htm">Exhibit 4.4</A> to the Registrant&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for
the year ended December&nbsp;31, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1816736/000095017022003288/gmtx-20211231.htm">March&nbsp;10, 2022</A>, and as further supplemented by
the description of the Registrant&#146;s common stock set forth in the Registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4/A,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1816736/000114036122043943/ny20005172x8_s4a.htm">December&nbsp;1,
 2022</A>, including any amendments or reports filed for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All documents that we file (but not
those that we furnish) pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement shall
be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, and any previously filed documents. All documents that we file (but not those that we furnish) pursuant to
Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of any of the securities covered under this prospectus shall be deemed to be incorporated by reference
into this prospectus and will automatically update and supersede the information in this prospectus, the applicable prospectus supplement and any previously filed documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this prospectus or the applicable prospectus
supplement shall be deemed to be modified or superseded for purposes of this prospectus and such applicable prospectus supplement to the extent that a statement contained in this prospectus or such applicable prospectus supplement, or in any other
subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus and such applicable prospectus supplement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be
deemed, except as so modified or superseded, to constitute a part of this prospectus or such applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Documents incorporated by
reference are available from us without charge, excluding all exhibits unless specifically incorporated by reference as an exhibit to this prospectus and the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prospective investors may obtain documents incorporated by reference in this prospectus and the applicable
prospectus supplement at no cost by requesting them in writing or by telephone from us at our executive offices at: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Disc Medicine, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">321 Arsenal Street, Suite 101 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Watertown, MA 02472 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention:
Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(617) <FONT STYLE="white-space:nowrap">674-9274</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, together with any accompanying prospectus supplement, includes and incorporates by reference &#147;forward-looking statements&#148; within
the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Exchange Act. All statements other than statements
of historical facts contained in this prospectus, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plan, objectives of management and expected market growth, are
forward-looking statements. You can identify these forward-looking statements by the use of words such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148;
&#147;could,&#148; &#147;design,&#148; &#147;due,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;positioned,&#148; &#147;potential,&#148;
&#147;predict,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would&#148; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or
other comparable terminology. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated
in these statements. We believe these factors include, but are not limited to, those described under &#147;<I>Risk Factors</I>&#148; and include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, results, and cost of our research and development programs and our current and
future preclinical studies and clinical trials, including our ongoing Phase 1b/2 clinical trials of DISC-0974 and our ongoing Phase 1 clinical trial of DISC-3405, and including statements regarding the timing of initiation and completion of studies
or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to efficiently discover and develop product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and the potential to successfully manufacture our drug substances and product candidates for
preclinical use, for clinical trials and on a larger scale for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations necessary to complete further development and commercialization
of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize our products, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, and strategic plans for our business and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations
or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future agreements with third parties in connection with the commercialization of product candidates and any other
approved product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing
cost; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of global economic and political developments on our business, including rising inflation and capital
market disruptions, the current conflicts between Russia and Ukraine and between Israel and Hamas, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts
as well as the value of our common stock and our ability to access capital markets; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;<I>Risk Factors</I>.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and
other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. In evaluating such forward-looking
statements, you should specifically consider various factors that may cause actual results to differ materially from current expectations, including the risks outlined under the heading &#147;<I>Risk Factors</I>&#148; contained in this prospectus
and any related prospectus supplement or free writing prospectus, and in any other documents incorporated herein or therein (including in our most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> subsequent quarterly
reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and other filings we make with the SEC pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act). Any forward-looking statement in this prospectus or any related prospectus
supplement or free writing prospectus reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given
these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes
available in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market and Industry Data and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, together with any accompanying prospectus supplement and the information incorporated herein or therein by reference, also contains estimates,
projections and other information concerning our industry, our business and the markets for our product candidates, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical
conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this
information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government
data and similar sources. We have not independently verified the accuracy and completeness of such data, and in some cases, we do not expressly refer to the sources from which these data are derived. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trademarks </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disc Medicine, Inc., the Disc logo and our
other registered or common law trademarks, trade names or service marks appearing in this prospectus are owned by us. This prospectus, any applicable prospectus supplement or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any information incorporated herein or therein may contain references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred
to in this prospectus, including logos, artwork and other visual displays, generally appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or TM symbols, but such references are not intended to indicate, in any way, that we
will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#146; trade names or trademarks to imply a
relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, service marks and trade names included or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing
prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_5"></A>ABOUT THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following highlights information about the Registrant and our business contained elsewhere or incorporated by reference in this prospectus. It is not
complete and does not contain all of the information that you should consider before investing in any of our securities. You should carefully read this prospectus together with the more detailed information incorporated by reference in this
prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. We have assembled a portfolio of clinical and preclinical product candidates that
aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Our current pipeline includes bitopertin for the treatment of erythropoietic
porphyrias, or EPs, including erythropoietic protoporphyria, or EPP, and <FONT STYLE="white-space:nowrap">X-linked</FONT> protoporphyria, or XLP, and Diamond-Blackfan Anemia, or DBA; DISC-0974 for the treatment of anemia of myelofibrosis, or MF, and
anemia of chronic kidney disease, or CKD; and DISC-3405 (formerly <FONT STYLE="white-space:nowrap">MWTX-003)</FONT> for the treatment of polycythemia vera, or PV, and other hematologic disorders. In addition, our preclinical programs also include
DISC-0998, for the treatment of anemia associated with inflammatory diseases. Our approach to product candidate development leverages well-understood molecular mechanisms that have been validated in humans. We believe that each of our product
candidates, if approved, has the potential to improve the lives of patients suffering from hematologic diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bitopertin is the lead product candidate
in our heme biosynthesis modulation portfolio. Bitopertin was previously evaluated by F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd and <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Inc., or collectively, Roche, in a
comprehensive clinical program in over 4,000 individuals in other indications which demonstrated the activity of bitopertin as a glycine transporter 1, or GlyT1, inhibitor and its effect on heme biosynthesis. We are initially developing bitopertin
for the treatment of EPs, including EPP and XLP. In July 2022, we initiated BEACON, a Phase 2 open-label, parallel-dose clinical trial of bitopertin in EPP and XLP patients that is being conducted at sites in Australia. In October 2022, we initiated
AURORA, a Phase 2, randomized, double-blind, placebo-controlled clinical trial of bitopertin in EPP patients that is being conducted at sites in the United States. We presented interim data from BEACON in June and December 2023, and we presented
topline data from AURORA in April 2024. Additional analyses of the BEACON and AURORA trials were presented in June 2024. We expect to have regulatory interactions to define optimal registrational endpoints moving forward in EPP in the second half of
2024. We entered into a collaborative research and development agreement with the National Institutes of Health, or NIH, to conduct an <FONT STYLE="white-space:nowrap">NIH-sponsored</FONT> clinical trial of bitopertin in DBA. The FDA authorized the
clinical trial to proceed and the trial began in July 2023. We are planning additional trials of bitopertin in other indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DISC-0974 is the lead
product candidate in our iron homeostasis portfolio and was <FONT STYLE="white-space:nowrap">in-licensed</FONT> from AbbVie Deutschland GmbH&nbsp;&amp; Co. KG, or AbbVie. DISC-0974 is designed to suppress hepcidin production and increase serum iron
levels. We submitted an IND to the FDA for DISC-0974 in June 2021, received clearance in July 2021, and participants completed a Phase 1 clinical trial in healthy volunteers in the U.S. in June 2022 with results showing an acceptable tolerability
profile and evidence of target engagement, iron mobilization and augmented erythropoiesis. We initiated a Phase 1b/2 clinical trial in June 2022 in patients with anemia of MF, and initiated a separate Phase 1b/2 clinical trial in February 2023 in
patients with <FONT STYLE="white-space:nowrap">non-dialysis</FONT> dependent CKD and anemia. We presented interim data from both of these trials in December 2023 and presented additional interim data for anemia of MF in June 2024, including safety
and changes in hepcidin, iron, and hemoglobin levels for additional patients, as well as longer <FONT STYLE="white-space:nowrap">follow-up.</FONT> We anticipate presenting additional interim data for
<FONT STYLE="white-space:nowrap">non-dialysis</FONT> dependent CKD and anemia in second half of 2024. In addition, we are developing a preclinical anti-hemojuvelin, or HJV, monoclonal antibody, DISC-0998, which also targets hepcidin suppression and
was </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">in-licensed</FONT> from AbbVie. DISC-0998 is designed to increase serum iron levels and has an extended serum
half-life as compared to DISC-0974. We believe this profile may be desirable in certain subsets of patients with anemia associated with inflammatory diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lastly, we are developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6, or
TMPRSS6, that we licensed from Mabwell Therapeutics, Inc., or Mabwell. DISC-3405 is part of our iron homeostasis portfolio and is designed to induce hepcidin production and reduce serum iron levels. An IND for DISC-3405 was cleared by the FDA, and a
Phase 1 clinical trial in healthy adult volunteers was initiated in October 2023. Interim data was presented from the single-ascending dose (SAD) portion of the Phase 1 clinical trial of DISC-3405 in healthy volunteers in June 2024. We anticipate
presenting data from the multiple-ascending dose (MAD) portion of the Phase 1 healthy volunteer study of DISC-3405 in the fourth quarter of 2024. We expect to develop DISC-3405 for the treatment of PV and other hematologic disorders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger with Gemini </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;9, 2022, Gemini
Therapeutics, Inc., a Delaware corporation (&#147;Gemini&#148;), Gemstone Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gemini (&#147;Merger Sub&#148;), and Disc Medicine, Inc., a Delaware corporation (&#147;Private
Disc&#148;), entered into an Agreement and Plan of Merger and Reorganization (the &#147;Merger Agreement&#148;). The merger was completed on December&nbsp;29, 2022. In accordance with the Merger Agreement, the Merger Sub merged with and into Private
Disc, with Private Disc surviving as a wholly-owned subsidiary of the Company (the &#147;merger&#148;). Gemini changed its name to Disc Medicine Inc., and Private Disc, which remains as a wholly-owned subsidiary of the Company, changed its name to
Disc Medicine Opco, Inc. On December&nbsp;30, 2022, the combined company&#146;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#147;IRON.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, references herein to &#147;Disc,&#148; the &#147;Company,&#148; or the &#147;combined company&#148;, refer to Disc Medicine,
Inc. on a post-merger basis, and the term &#147;Private Disc&#148; refers to the business of privately-held Disc Medicine, Inc., prior to completion of the merger. References to Gemini refer to Gemini Therapeutics, Inc. prior to completion of the
merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disc Medicine, Inc.
was originally incorporated under the laws of the state of Delaware in October 2017, and changed its name to Disc Medicine Opco, Inc., or Disc Opco, in December 2022. On December&nbsp;29, 2022, we completed our business combination with Gemini, in
accordance with the terms of the Merger Agreement, pursuant to which, among other matters, Merger Sub merged with and into Disc Opco, with Disc Opco continuing as a wholly owned subsidiary of us and the surviving corporation of the merger, or the
Merger. In connection with the closing of the Merger, Gemini changed its name to Disc Medicine, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 321
Arsenal Street, Suite 101, Watertown, MA 02472, and our telephone number is (617) <FONT STYLE="white-space:nowrap">674-9274.</FONT> Our website address is www.discmedicine.com. We do not incorporate the information on or accessible through our
website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. Our common stock is listed on Nasdaq under the symbol &#147;IRON.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current
Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act are available, free of charge, on or through our website as soon as reasonably
practicable after such reports and amendments are electronically filed with or furnished to the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding our filings at<I>
www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information about our Company, please refer to other documents we have filed with the SEC and that are incorporated by
reference into this prospectus, as listed under the heading &#147;<I>Incorporation of Certain Information by Reference</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the &#147;JOBS Act&#148;). As
an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to only disclose two years of audited financial statements in addition to any required unaudited
interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any
golden parachute arrangements not previously approved; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until the end of the fiscal year following the fifth anniversary of our initial
public offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross
revenue of $1.235&nbsp;billion or more; (ii)&nbsp;December&nbsp;31, 2025; (iii) the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the last day of the fiscal year in
which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June
30th. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus supplement. Accordingly, the information contained herein may be different from the
information you receive from other public companies in which you hold stock. Subject to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation, omitting an auditor&#146;s
attestation report on our system of internal controls over financial reporting otherwise required by Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no
longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than $250&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenues are less than $100&nbsp;million during the most recently completed fiscal
year and our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than $700&nbsp;million measured on the last business day of our second fiscal quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_6"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities involves certain risks. Before you invest in any of our common stock, preferred stock, debt securities, warrants or units, in
addition to the other information included in, or incorporated by reference into, this prospectus, you should carefully consider the risk factors contained in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> which
is on file with the SEC and is incorporated herein by reference, as updated by our subsequent annual, quarterly and other reports we file with the SEC, as well as any amendments thereto, which are incorporated by reference into this prospectus. See
&#147;<I>Where You Can Find More Information</I>&#148; for information about how to obtain a copy of these documents. You should also carefully consider the risks and other information that may be contained in, or incorporated by reference into, any
prospectus supplement relating to specific offerings of securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_8"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise described in the applicable prospectus supplement, we intend to use the net proceeds from the sale of any securities described in this
prospectus for general corporate purposes, which may include research and development and preclinical and clinical development costs to support the advancement of our product candidates; working capital; capital expenditures; general and
administrative expenses; and other general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may set forth additional information concerning our expected use of net proceeds from
sales of securities in the applicable prospectus supplement relating to the specific offering. Pending use of net proceeds as described above, we may temporarily invest the net proceeds in a variety of capital preservation instruments, including
high quality, investment grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government, or may hold such proceeds as cash, until they are used for their stated purpose. We have not determined the amount of net
proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_9"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of
cash dividends, if any, in the future will solely be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements,
business prospects and other factors our board of directors may deem relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_10"></A>GENERAL DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer shares of common or preferred stock, various series of senior or subordinated debt securities, warrants, or units consisting of combinations of
the foregoing, in each case from time to time under this prospectus, together with the applicable prospectus supplement, at prices and on terms to be determined by market conditions at the time of offering. This prospectus provides you with a
general description of the securities we may offer. At the time we offer a particular type or series of securities, we will provide an applicable prospectus supplement describing the specific amounts, prices and other important terms of the
securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation or classification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aggregate principal amount or aggregate offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or other rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rates and times of payment of interest, dividends or other payments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liquidation preference; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">original issue discount; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maturity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ranking; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictive covenants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption, conversion, exercise, exchange, settlement or sinking fund terms, including prices or rates, and any
provisions for changes to or adjustments in such prices or rates and in the securities or other property receivable upon conversion, exercise, exchange or settlement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market listing arrangements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">important U.S. federal income tax considerations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus may not be used to offer or sell securities unless accompanied by an applicable prospectus supplement. The applicable prospectus supplement
may add, update or change information contained in this prospectus or in documents incorporated by reference in this prospectus. You should read the applicable prospectus supplement related to any securities being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities to or through underwriters, dealers or agents, directly to purchasers or through a combination of any of these methods of sale or
as otherwise set forth under &#147;<I>Plan of Distribution</I>&#148;. We and our underwriters, dealers or agents reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters
or agents, we will include in the applicable prospectus supplement (i)&nbsp;the names of the underwriters or agents and applicable fees, discounts and commissions to be paid to them; (ii)&nbsp;details regarding over-allotment options, if any; and
(iii)&nbsp;net proceeds to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following descriptions are not complete and may not contain all the information you should consider before investing
in any securities we may offer hereunder; they are summarized from, and qualified by reference to, our amended and restated certificate of incorporation, amended and restated bylaws and the other documents referred to in the descriptions, all of
which are or will be publicly filed with the SEC, as applicable. See &#147;<I>Where You Can Find More Information</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_11"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary description of our common stock and preferred stock, together with the additional information we include in any applicable prospectus
supplements, summarizes the material terms and provisions of our capital stock. The following description of our capital stock is intended as a summary only, does not purport to be complete and is subject to, and qualified in its entirety by, our
amended and restated certificate of incorporation and amended and restated bylaws, which are exhibits to the registration statement of which this prospectus forms a part, and by applicable law. The terms of our common stock and preferred stock may
also be affected by Delaware law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized Capital Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value
$0.0001 per share, all of which preferred stock is undesignated. As of June&nbsp;30, 2024, we had 29,707,997 shares of our common stock outstanding and no shares of preferred stock outstanding. Unless our board of directors determines otherwise, we
will issue all shares of our capital stock in uncertificated form. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common
stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights
of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after
payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. When we issue shares of common stock under this prospectus, when issued and paid for, the shares will be validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange Listing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Market under the symbol &#147;IRON.&#148; On August&nbsp;7, 2024, the closing price for our common stock, as
reported on The Nasdaq Global Market, was $41.27 per share. As of June&nbsp;30, 2024, we had estimated approximately 19 stockholders of record. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer Agent and Registrar </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent
and registrar for our common stock is Broadridge Corporate Issuer Solutions, LLC. The transfer agent and registrar&#146;s address is 51 Mercedes Way, Edgewood, NY 11717. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one
or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking
fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In
addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. We have no shares of preferred stock outstanding, and we have no present plan to issue
any shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of authorizing our board of directors to issue preferred stock in one or more series and determine the number
of shares in the series and its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. Examples of rights and preferences that our board of directors may fix are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dividend rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dividend rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terms of redemption; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liquidation preferences. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The existence of authorized but unissued shares of undesignated preferred stock may enable our board of directors to render more difficult or to discourage an
attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best
interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the
proposed acquirer, stockholder or stockholder group. The rights of holders of our common stock described above, will be subject to, and may be adversely affected by, the rights of any preferred stock that we may designate and issue in the future.
The issuance of shares of undesignated preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting
rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Series of Preferred
Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will incorporate by reference as an exhibit to the registration statement, which includes this prospectus, the form of any certificate of
designation that describes the terms of any additional series of preferred stock we may offer pursuant to this prospectus. This description and the applicable prospectus supplement will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares authorized; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate, period and payment date, and method of calculation for dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those
redemption and repurchase rights; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price,
or how it will be calculated, and the conversion period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or
how it will be calculated, and the exchange period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemptive rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material United States federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate,
dissolve or wind up our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the
series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we issue shares of preferred stock under this prospectus, the shares will fully be paid and nonassessable and will not be subject
to any preemptive or similar rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of an estimated 5.0&nbsp;million shares of our common stock, or their transferees, are entitled to the registration rights set forth below with
respect to registration of the resale of such shares under the Securities Act pursuant to the investors&#146; rights agreement, by and among us and certain of our stockholders. Generally, in an underwritten offering, the managing underwriter, if
any, has the right, subject to specified conditions and limitations, to limit the number of shares the holders may include. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2022 Registration
Rights Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party to a registration rights agreement, or the 2022 Registration Rights Agreement, with certain holders of our capital
stock, or the 2022 Investors, pursuant to which we (i)&nbsp;agreed to register for resale shares of our common stock issued to the 2022 Investors pursuant to the Merger Agreement, or the Registrable Securities, and (ii)&nbsp;granted certain other
registration rights to the 2022 Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, the 2022 Registration Rights Agreement provides for the following registration rights: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Shelf registration rights</I>. Following the completion of the merger as contemplated by the Merger Agreement,
we were required to file with the SEC, a shelf registration statement registering the resale of the Registrable Securities, and use our commercially reasonable efforts to have such registration statement declared effective by the SEC as promptly as
possible. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expenses and indemnification</I>. The fees, costs and expenses of registrations pursuant to the registration
rights granted to the 2022 Investors under the 2022 Registration Rights Agreement will be borne by us. The 2022 Registration Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of
Registrable Securities in the event of material misstatements or omissions in the registration statement attributable to us, and holders of Registrable Securities are obligated to indemnify us for material misstatements or omissions attributable to
them. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Registration Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a party to a registration rights agreement, or the 2021 Registration Rights Agreement, pursuant to which, among other things, certain holders of capital
stock, including certain investors of FS Development Corporation, a Delaware corporation, or the FSDC Investors, certain entities affiliated with Atlas Ventures, entities affiliated with Lightstone Ventures, OrbiMed Private Investments VI, LP, and
Wu Capital Investment LLC, or collectively, the Major Investors and together with the FSDC Investors, the Investors, were granted certain registration rights with respect to Registrable Securities, as defined in the 2021 Registration Rights
Agreement, held by them, subject to certain conditions and limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, the 2021 Registration Rights Agreement provides for the following
registration rights: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Demand registration rights</I>. We are required, upon the written request of either (i)&nbsp;FSDC Investors
holding a majority of the Registrable Securities held by all FSDC Investors or (ii)&nbsp;Major Investors holding a majority of the Registrable Securities held by all Major Investors, to file a registration statement under the Securities Act on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> or any similar long-form registration statement or, if then available, on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> and use reasonable best efforts to effect the registration of all or part of their
registrable securities requested to be included in such registration by the Investors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Shelf registration rights</I>. A shelf registration statement pursuant to Rule 415 of Securities Act, was
filed on February&nbsp;17, 2021 and became effective on April&nbsp;28, 2021. At any time we have an effective shelf registration statement, if we receive a request from Investors holding registrable securities with an estimated market value of at
least $5,000,000, to effect an underwritten shelf takedown, we shall use our reasonable best efforts to as expeditiously as possible effect the underwritten shelf takedown. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Limits on demand registration rights and shelf registration rights.</I> We shall not be obligated to effect:
(a)&nbsp;more than one (1)&nbsp;demand registration or underwritten shelf takedown during any <FONT STYLE="white-space:nowrap">six-month</FONT> period; (b)&nbsp;any demand registration at any time there is an effective resale shelf registration
statement on file with the SEC; (c)&nbsp;more than two underwritten demand registrations in respect of all registrable securities held by the FSDC Investors, including those made under a shelf registration statement, or (d)&nbsp;more than two
underwritten demand registrations in respect of all registrable securities held by the Major Investors, including those made under a shelf registration statement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Piggyback registration rights</I>. At any time after the first anniversary of the closing date, if we propose
to file a registration statement to register any of our equity securities under the Securities Act or to conduct a public offering, either for our own account or for the account of any other person, subject to certain exceptions, the Investors are
entitled to include their registrable securities in such registration statement, subject to customary <FONT STYLE="white-space:nowrap">cut-back</FONT> rights. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expenses and indemnification</I>. All fees, costs and expenses of underwritten registrations will be borne by
us and underwriting discounts and selling commissions will be borne by the holders of the shares being registered. The 2021 Registration Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify
holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and holders of registrable securities are obligated to indemnify us for material misstatements or omissions
attributable to them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Registrable securities</I>. Securities of ours shall cease to be registrable securities upon the earlier of
(i)&nbsp;tenth anniversary of February&nbsp;5, 2021 and (ii)&nbsp;the date as of which (1)&nbsp;a registration statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have
been disposed of in accordance with such registration statement, or (2)&nbsp;such securities shall have been transferred pursuant to Rule 144 of the Securities Act, or with respect to any Investor, securities of such Investor shall cease to be
registrable securities, on the earlier of (x)&nbsp;the date such Investor ceases to hold at least 1% of the registrable securities or (y)&nbsp;if such Investor is an individual and such Investor is a director or an executive officer of Disc or FS
Development </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Corporation as of immediately prior to the consummation of the business combination, the date when such Investor is permitted to sell the Registrable Securities under Rule 144 (or any similar
provision) under the Securities Act without limitation on the amount of securities sold or the manner of sale. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized but
Unissued Capital Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Delaware General Corporation Law does not require stockholder approval for any issuance of authorized shares. However, the
listing requirements of Nasdaq, which would apply so long as our common stock remains listed on Nasdaq, require stockholder approval of certain issuances equal to or exceeding 20% of the then outstanding voting power or then outstanding number of
shares of common stock. These additional shares may be used for a variety of corporate purposes, including future public offerings, to raise additional capital or to facilitate acquisitions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One of the effects of the existence of unissued and unreserved common stock or preferred stock may be to enable our board of directors to issue shares to
persons friendly to current management, which issuance could render more difficult or discourage an attempt to obtain control of our company by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our
management and possibly deprive our stockholders of opportunities to sell their shares of common stock at prices higher than prevailing market prices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could
make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could
make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are
also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or
unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware anti-takeover statute </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not
governed by Section&nbsp;203 of the Delaware General Corporation Law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated preferred stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or
preferences that could impede the success of any attempt to effect a change in control of our company. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special stockholder meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and
restated certificate of incorporation provides that a special meeting of stockholders may be called at any time by our board of directors, but such special meetings may not be called by the stockholders or any other person or persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for advance notification of stockholder nominations and proposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws contain advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as
directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No stockholder
action by written consent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation does not allow stockholders to act by written consent without a
meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified board; election and removal of directors; filling vacancies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes, divided as nearly as equal in number as possible. The directors in each class serve for a three-year
term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective
three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of
incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the voting power of the then outstanding voting stock. Any
vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board, may only be filled by a resolution of the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This system of electing and removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting
to obtain control of us because it generally makes it more difficult for stockholders to replace a majority of the directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of forum
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws provide that, unless we consent in writing to the selection
of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf;
any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers, employees or stockholders to us or to our stockholders; any action asserting a claim against us arising pursuant to the Delaware General Corporation
Law, our amended and restated certificate of incorporation or our amended and restated bylaws (as either may be amended from time to time); any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of
incorporation or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. As a result, any action brought by any of our stockholders with regard to any of these matters will need
to be filed in the Court of Chancery of the State of Delaware and cannot be filed in any other jurisdiction; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or
the Securities Act. In addition, unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts will be the sole and exclusive forum for resolving any action asserting a
claim arising under the Securities Act. Such provision is intended to benefit and may be enforced by us, our officers and directors, employees and agents, including the underwriters and any other professional or entity who has prepared or certified
any part of this prospectus. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court,
subject to applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although our amended and restated certificate of incorporation and amended and restated bylaws contain the choice of forum
provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum
that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims or make such lawsuits more costly for stockholders, although our stockholders
will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of charter
provisions or bylaws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws may be amended or repealed by our board of directors or by the affirmative vote of the
holders of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the voting power of all of the shares of the capital stock of our Company entitled to vote on such amendment or repeal, voting as one class; provided, however, that if
our board of directors recommends that stockholders approve such amendment or repeal, such amendment or repeal shall only require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or
repeal, voting together as a single class. The affirmative vote of the holders of the majority of the outstanding shares of capital stock of our Company entitled to vote thereon as a class, and the affirmative vote of the holders of a majority of
the outstanding shares of each class entitled to vote thereon as a class voting together as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation and our amended and restated bylaws could have
the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These
provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_12"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section describes the general terms and provisions of our debt securities that we may issue from time to time. We may issue debt securities, in one or
more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any future debt securities we may offer under this prospectus, the applicable
prospectus supplement or free writing prospectus will describe the specific terms of any debt securities offered through that prospectus supplement or free writing prospectus. The terms of any debt securities we offer under a prospectus supplement
or free writing prospectus may differ from the terms we describe below. Unless the context requires otherwise, whenever we refer to the &#147;indentures,&#148; we also are referring to any supplemental indentures that specify the terms of a
particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will issue any senior debt securities under the senior indenture that we will enter into with the trustee named
in the senior indenture. We will issue any subordinated debt securities under the subordinated indenture that we will enter into with the trustee named in the subordinated indenture. We have filed forms of these documents as exhibits to the
registration statement, of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this
prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indentures will be qualified under the Trust
Indenture Act of 1939, as amended, or the Trust Indenture Act. We use the term &#147;trustee&#148; to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and
qualified in their entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplement or free writing prospectus and any related free
writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete applicable indenture that contains the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior
indenture and the subordinated indenture are identical. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement or free writing prospectus the terms of the series of debt securities being offered, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount being offered, and if a series, the total amount authorized and the total amount
outstanding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not we will issue the series of debt securities in global form, and, if so, the terms and who the
depository will be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a
person who is not a United States person for tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the subordination of any series of subordinated debt; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place where payments will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, after which, the conditions upon which, and the price at which, we may, at our option, redeem
the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund or
analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option, to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the indenture will restrict our ability to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue additional securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create liens; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redeem capital stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">place restrictions on our subsidiaries&#146; ability to pay dividends, make distributions or transfer assets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make investments or other restricted payments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell or otherwise dispose of assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into sale-leaseback transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">engage in transactions with stockholders or affiliates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue or sell stock of our subsidiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effect a consolidation or merger; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based,
asset-based or other financial ratios; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of certain material or special United States federal income tax considerations applicable to the
debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information describing any book-entry features; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions for a sinking fund purchase or other analogous fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of the provisions in the indenture on discharge; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities are to be offered at a price such that they will be deemed to be offered at an
&#147;original issue discount&#148; as defined in paragraph (a)&nbsp;of Section&nbsp;1273 of the Internal Revenue Code of 1986, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities,
including any additional events of default or covenants provided with respect to the debt securities, and any terms that may be required by us or advisable under applicable laws or regulations or advisable in connection with the marketing of the
debt securities. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus supplement or free writing prospectus the terms on which a series of debt securities may be convertible into or
exchangeable for our common stock, our preferred stock or other securities (including securities of a third-party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may
include provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third-party) that the holders of the series of debt securities receive would be subject to adjustment.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or
otherwise dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate. If the debt securities are convertible
into or exchangeable for other securities of ours or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities into securities
that the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger or sale. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events
of Default Under the Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement or free writing prospectus applicable to a particular series
of debt securities, the following are events of default under the indentures with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment
has not been extended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon
redemption or repurchase or otherwise, and the time for payment has not been extended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other
than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive notice from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of
the applicable series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in each applicable prospectus supplement or free writing prospectus any additional events of default relating to the relevant series of debt
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in
the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare
the unpaid principal, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the unpaid principal, premium, if any, and accrued interest,
if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may
waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in
accordance with the indenture. Any waiver shall cure the default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indentures, if an event of default
under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities,
unless such holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The holders of a majority in principal amount of the outstanding debt securities of any series will have the
right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of the debt securities of
any series will have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request, and such holders have offered reasonable indemnity to the trustee or security satisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting the proceeding as trustee; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest
on, the debt securities, or other defaults that may be specified in the applicable prospectus supplement or free writing prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will periodically
file statements with the trustee regarding our compliance with specified covenants in the indentures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture for any series of debt securities that we may issue, we and the trustee may change an indenture without the consent of
any holders with respect to the following specific matters: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fix any ambiguity, defect or inconsistency in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under &#147;<I>Description of Debt Securities-Consolidation, Merger
or</I> <I>Sale</I>;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided under &#147;<I>Description of Debt Securities-General</I>,&#148; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights
of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment hereunder by a successor trustee;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities and to make all appropriate changes for such purpose;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants such new covenants, restrictions, conditions or provisions for the benefit of the
holders, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred to us in the indenture; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to change anything that does not materially adversely affect the interests of any holder of debt securities of
any series. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the
trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any series of debt securities
that we may issue or as otherwise provided in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any
outstanding debt securities affected: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the stated maturity of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption or repurchase of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each indenture provides that, subject to the terms of the indenture and any limitation otherwise provided in the prospectus supplement or free writing
prospectus applicable to a particular series of debt securities, we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any
premium and interest on, the debt securities of the series on the dates payments are due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus
supplement or free writing prospectus, in denominations of $1,000 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and any integral multiple thereof. The indentures provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited
with, or on behalf of, The Depository Trust Company or another depository named by us and identified in a prospectus supplement or free writing prospectus with respect to that series. At the option of the holder, subject to the terms of the
indentures and the limitations applicable to global securities described in the applicable prospectus supplement or free writing prospectus, the holder of the debt securities of any series can exchange the debt securities for other debt securities
of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indentures and the
limitations applicable to global securities set forth in the applicable prospectus supplement or free writing prospectus, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or
with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in
the debt securities that the holder presents for transfer or exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will name in the applicable prospectus supplement or free writing prospectus the security registrar, and any transfer agent in addition to the security
registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except
that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are
specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt
securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying
Agents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement or free writing prospectus, we will make payment of the interest on any
debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us,
except that unless we otherwise indicate in the applicable prospectus supplement or free writing prospectus, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate
in the applicable prospectus supplement or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
free writing prospectus, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the
applicable prospectus supplement or free writing prospectus any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a
particular series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt
securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indentures and the debt securities
will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ranking of Debt Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The subordinated debt
securities will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement or free writing prospectus. The subordinated indenture does not limit the amount of subordinated
debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The senior debt securities will rank
equally in right of payment to all our other senior unsecured debt. The senior indenture does not limit the amount of senior debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_13"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the material terms and
provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular
terms of any series of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms described below.
Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement, which includes this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of common
stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement. We will enter into the warrant
agreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of warrants, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and
the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the periods during which, and places at which, the warrants are exercisable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner of exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreement and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal income tax consequences of holding or exercising the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_14"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units comprised of shares of common stock, shares of preferred stock, debt securities and warrants in any combination. We may issue units in such
amounts and in as many distinct series as we wish. This section outlines certain provisions of the units that we may issue. If we issue units, they will be issued under one or more unit agreements to be entered into between us and a bank or other
financial institution, as unit agent. The information described in this section may not be complete in all respects and is qualified entirely by reference to the unit agreement with respect to the units of any particular series. The specific terms
of any series of units offered will be described in the applicable prospectus supplement. If so described in a particular supplement, the specific terms of any series of units may differ from the general description of terms presented below. We urge
you to read any prospectus supplement related to any series of units we may offer, as well as the complete unit agreement and unit certificate that contain the terms of the units. If we issue units, forms of unit agreements and unit certificates
relating to such units will be incorporated by reference as exhibits to the registration statement, which includes this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each unit that we may
issue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a
unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The applicable prospectus supplement may describe: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the units and of the securities comprising the units, including whether and under
what circumstances those securities may be held or transferred separately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions of the governing unit agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which such units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicable United States federal income tax considerations relating to the units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities
comprising the units; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and of the securities comprising the units. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions described in this section, as well as those described under &#147;<I>Description of Capital Stock</I>,&#148; &#147;<I>Description of Debt
Securities&#148;</I> and &#147;<I>Description of Warrants</I>&#148; will apply to the securities included in each unit, to the extent relevant and as may be updated in any prospectus supplements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance in Series </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units in such amounts
and in as many distinct series as we wish. This section summarizes terms of the units that apply generally to all series. Most of the financial and other specific terms of a particular series of units will be described in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unit Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will issue the units
under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit agent. We may add, replace or terminate unit agents from time to time. We will identify the unit agreement under which each series of
units will be issued and the unit agent under that agreement in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following provisions will generally apply to all unit agreements unless otherwise stated in the
applicable prospectus supplement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification without Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the applicable unit agent may amend any unit or unit agreement without the consent of any holder: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity; any provisions of the governing unit agreement that differ from those described below;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to correct or supplement any defective or inconsistent provision; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any other change that we believe is necessary or desirable and will not adversely affect the interests of
the affected holders in any material respect. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not need any approval to make changes that affect only units to be issued after the
changes take effect. We may also make changes that do not adversely affect a particular unit in any material respect, even if they adversely affect other units in a material respect. In those cases, we do not need to obtain the approval of the
holder of the unaffected unit; we need only obtain any required approvals from the holders of the affected units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification with Consent
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not amend any particular unit or a unit agreement with respect to any particular unit unless we obtain the consent of the holder of that
unit, if the amendment would: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impair any right of the holder to exercise or enforce any right under a security included in the unit if the
terms of that security require the consent of the holder to any changes that would impair the exercise or enforcement of that right; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage of outstanding units or any series or class the consent of whose holders is required to
amend that series or class, or the applicable unit agreement with respect to that series or class, as described below. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any other change
to a particular unit agreement and the units issued under that agreement would require the following approval: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the change affects only the units of a particular series issued under that agreement, the change must be
approved by the holders of a majority of the outstanding units of that series; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the change affects the units of more than one series issued under that agreement, it must be approved by the
holders of a majority of all outstanding units of all series affected by the change, with the units of all the affected series voting together as one class for this purpose. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions regarding changes with majority approval also apply to changes affecting any securities issued under a unit agreement, as the governing
document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In each case, the required approval must be given by written consent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unit Agreements Will Not Be Qualified under Trust Indenture Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No unit agreement will be qualified as an indenture, and no unit agent will be required to qualify as a trustee, under the Trust Indenture Act. Therefore,
holders of units issued under unit agreements will not have the protections of the Trust Indenture Act with respect to their units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mergers and
Similar Transactions Permitted; No Restrictive Covenants or Events of Default </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unit agreements will not restrict our ability to merge or
consolidate with, or sell our assets to, another corporation or other entity or to engage in any other transactions. If at any time we merge or consolidate with, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sell our assets substantially as an entirety to, another corporation or other entity, the successor entity will succeed to and assume our obligations under the unit agreements. We will then be
relieved of any further obligation under these agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unit agreements will not include any restrictions on our ability to put liens on our
assets, nor will they restrict our ability to sell our assets. The unit agreements also will not provide for any events of default or remedies upon the occurrence of any events of default. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governing Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unit agreements and the units
will be governed by New York law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form, Exchange and Transfer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will issue each unit in global, i.e., book-entry, form only. Units in book-entry form will be represented by a global security registered in the name of a
depositary, which will be the holder of all the units represented by the global security. Those who own beneficial interests in a unit will do so through participants in the depositary&#146;s system, and the rights of these indirect owners will be
governed solely by the applicable procedures of the depositary and its participants. We will describe book-entry securities, and other terms regarding the issuance and registration of the units in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each unit and all securities comprising the unit will be issued in the same form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we issue any units in registered, <FONT STYLE="white-space:nowrap">non-global</FONT> form, the following will apply to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The units will be issued in the denominations stated in the applicable prospectus supplement. Holders may exchange their units for units of smaller
denominations or combined into fewer units of larger denominations, as long as the total amount is not changed. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Holders may exchange or transfer their units at the office of the unit agent. Holders may also replace lost,
stolen, destroyed or mutilated units at that office. We may appoint another entity to perform these functions or perform them ourselves. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Holders will not be required to pay a service charge to transfer or exchange their units, but they may be
required to pay for any tax or other governmental charge associated with the transfer or exchange. The transfer or exchange, and any replacement, will be made only if our transfer agent is satisfied with the holder&#146;s proof of legal ownership.
The transfer agent may also require an indemnity before replacing any units. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we have the right to redeem, accelerate or settle any units before their maturity, and we exercise our right
as to less than all those units or other securities, we may block the exchange or transfer of those units during the period beginning 15 days before the day we mail the notice of exercise and ending on the day of that mailing, in order to freeze the
list of holders to prepare the mailing. We may also refuse to register transfers of or exchange any unit selected for early settlement, except that we will continue to permit transfers and exchanges of the unsettled portion of any unit being
partially settled. We may also block the transfer or exchange of any unit in this manner if the unit includes securities that are or may be selected for early settlement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only the depositary will be entitled to transfer or exchange a unit in global form, since it will be the sole holder of the unit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments and Notices </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In making payments and
giving notices with respect to our units, we will follow the procedures as described in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_15"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the offered securities in and outside the United States (1)&nbsp;through underwriters or dealers, (2)&nbsp;directly to one or more purchasers,
including to a limited number of institutional purchasers, to a single purchaser or to our affiliates and stockholders, (3)&nbsp;through agents or (4)&nbsp;through a combination of any of these methods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If underwriters or dealers are used in the sale, the securities will be acquired by the underwriters or dealers for their own account and may be resold from
time to time in one or more transactions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in one or more transactions at a fixed price or prices, which may be changed from time to time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market</FONT></FONT>
offerings,&#148; within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a market maker or into an existing trading market on an exchange or otherwise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to those prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will set forth the following information to the extent applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of any underwriters, dealers or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any managing underwriter or underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the net proceeds from the sale of the securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delayed delivery arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any underwriting discounts, commissions and other items constituting underwriters&#146; compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any initial public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any commissions paid to agents. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale through Underwriters or Dealers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any securities
are offered through underwriters, the underwriters will acquire the securities for their own account and may resell them from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying
prices determined at the time of sale. Underwriters may offer and sell securities to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters. Unless
otherwise provided in the applicable prospectus supplement, the obligations of the underwriters to purchase the securities will be subject to certain conditions, and the underwriters will be obligated to purchase all of the offered securities if
they purchase any of them. In connection with the sale of securities, underwriters may be deemed to have received compensation from us in the form of underwriting discounts or commissions and dealers may receive compensation from the underwriters in
the form of discounts or concessions. The underwriters may change from time to time any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of securities, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the
securities. Specifically, the underwriters may overallot in connection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the offering, creating a short position in the securities for their account. In addition, to cover overallotments or to stabilize the price of the shares, the underwriters may bid for, and
purchase, shares in the open market. Finally, an underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases previously distributed shares
in transactions to cover syndicate short positions, in stabilization transactions, or otherwise. Any of these activities may stabilize or maintain the market price of the offered securities above independent market levels. The underwriters are not
required to engage in these activities, and may discontinue any of these activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some or all of the securities that we offer through this
prospectus may be new issues of securities with no established trading market. Any underwriters to whom we sell securities for public offering and sale may make a market in those securities, but they will not be obligated to do so and they may
discontinue any market making at any time without notice. Accordingly, we cannot assure you of the liquidity of, or continued trading markets for, any securities offered pursuant to this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any securities are offered through dealers, we will sell the securities to them as principals. They may then resell those securities to the public at
varying prices determined by the dealers at the time of resale. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Direct Sales and Sales through Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to purchasers. If the securities are sold directly to institutional investors or others who may be deemed to be
underwriters within the meaning of the Securities Act with respect to any sale of those securities, we will describe the terms of any such sales in the applicable prospectus supplement. We may also sell the securities through agents designated from
time to time. Sales may be made by means of ordinary brokers&#146; transactions on The Nasdaq Global Market at market prices, in block transactions and such other transactions as agreed by us and any agent. In the applicable prospectus supplement,
we will name any agent involved in the offer or sale of the offered securities, and we will describe any commissions payable to the agent. Unless otherwise provided in the applicable prospectus supplement, any agent will agree to use its reasonable
best efforts to solicit purchases for the period of its appointment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-the-Market</FONT></FONT> Offerings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that we make sales through one or more underwriters or agents in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> offerings, we will do so pursuant to the terms of a sales agency financing agreement or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">at-the-market</FONT></FONT> offering arrangement between us, on the one hand, and the underwriters or agents, on the other. If we engage in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> sales pursuant to any such agreement, we will issue and sell our securities through one or more underwriters or agents, which may act on an agency basis or
a principal basis. During the term of any such agreement, we may sell securities on a daily basis in exchange transactions or otherwise as we agree with the underwriters or agents. Any such agreement will provide that any securities sold will be
sold at prices related to the then prevailing market prices for our securities. Therefore, exact figures regarding proceeds that will be raised or commissions to be paid cannot be determined at this time. Pursuant to the terms of the agreement, we
may agree to sell, and the relevant underwriters or agents may agree to solicit offers to purchase blocks of our common stock or other securities. The terms of any such agreement will be set forth in more detail in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Remarketing Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offered
securities may also be offered and sold, if we so indicate in the applicable prospectus supplement, in connection with a remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or
more remarketing firms, acting as principals for their own accounts or as our agents. Any remarketing firm will be identified and the terms of its agreements, if any, with us and its compensation will be described in the applicable prospectus
supplement. Remarketing firms may be deemed to be underwriters of the offered securities under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delayed Delivery Contracts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we so indicate in the applicable prospectus supplement, we may authorize agents, underwriters or dealers to solicit offers by certain institutions to
purchase securities from us pursuant to contracts providing for payment and delivery on a specified future date. The applicable prospectus supplement will describe the conditions to those contracts and the commission payable for solicitation of
those contracts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may have
agreements with the agents, dealers, underwriters and remarketing firms to indemnify them against certain civil liabilities, including liabilities under the Securities Act, or to contribute with respect to payments that the agents, dealers or
underwriters may be required to make. Agents, dealers, underwriters and remarketing firms may be customers of, engage in transactions with or perform services for us in the ordinary course of their businesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each underwriter, dealer and agent participating in the distribution of any of the securities that are issuable in bearer form will agree that it will not
offer, sell or deliver, directly or indirectly, securities in bearer form in the United States or to United States persons, other than qualifying financial institutions, during the restricted period, as defined in United States Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.163-5(c)(2)(i)(D)(7).</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_16"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain legal matters in connection with this offering will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Additional legal matters may
be passed on for us, or any underwriters, dealers or agents by counsel we will name in the applicable prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912653_17"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Disc Medicine, Inc. appearing in Disc Medicine, Inc.&#146;s Annual Report (Form <FONT
STYLE="white-space:nowrap">10-K)</FONT> for the year ended December&nbsp;31, 2023, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and
incorporated herein by reference. Such consolidated financial statements are, and audited financial statements to be included in subsequently filed documents will be, incorporated herein in reliance upon the report of Ernst&nbsp;&amp; Young LLP
pertaining to such financial statements (to the extent covered by consents filed with the Securities and Exchange Commission) given on the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912653g96b12.jpg" ALT="LOGO" STYLE="width:4.50496in;height:0.701293in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Up to $200,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:170pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:170pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912653g18b66.jpg" ALT="LOGO" STYLE="width:1.88276in;height:0.362361in;">
 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>November&nbsp;15, 2024 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>d912653dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 107 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Calculation of Filing Fee Tables </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">424(b)(5) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Disc Medicine, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name
of Registrant as Specified in its Charter) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1: Newly Registered and Carry Forward Securities </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Security<BR>Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Security<BR>Class<BR>Title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Fee Calculation<BR>or Carry<BR>Forward<BR>Rule</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Amount<BR>Registered</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Proposed<BR>Maximum<BR>Offering<BR>Price<BR>Per Unit</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Maximum<BR>Aggregate<BR>Offering Price</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Fee Rate</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Amount of<BR>Registration<BR>Fee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="17" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Newly Registered Securities</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees&nbsp;to&nbsp;Be&nbsp;Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common&nbsp;Stock,<BR>$0.0001<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">par value<BR>per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">457(o)&nbsp;and&nbsp;457(r)(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$200,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$200,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">0.00015310</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000">$30,620</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees&nbsp;Previously</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Total&nbsp;Offering&nbsp;Amounts</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$200,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000">$30,620</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total&nbsp;Fees&nbsp;Previously&nbsp;Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Fee Offsets</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000">$25,144.84(2)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Net Fee Due</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$5,475.16</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registration fee is calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended
(the &#147;Securities Act&#148;), based on the proposed maximum aggregate offering price, and Rule 457(r) under the Securities Act. In accordance with Rules 456(b) and 457(r) under the Securities Act, the Registrant initially deferred payment of all
of the registration fee for Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3ASR</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-281359),</FONT> which was filed with the Securities and Exchange Commission (the
&#147;SEC&#148;) on August&nbsp;8, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 457(p) under the Securities Act, the registrant hereby applies $25,144.84 of the registration
fee previously paid in connection with the Prior Registration Statement (as defined below) to offset the registration fees that are payable in connection with the registration of securities on this registration statement. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 2: Fee Offset Claims and Sources </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Registrant<BR>or&nbsp;Filer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Name</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Form<BR>of<BR>Filing<BR>Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">File</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Number</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Initial</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Filing</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Date</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Filing</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Date</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Offset</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Claimed</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>Type<BR>Associated<BR>with Fee<BR>Offset<BR>Claimed</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>Title<BR>Associated<BR>with Fee<BR>Offset<BR>Claimed</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Unsold<BR>Securities<BR>Associated<BR>with Fee<BR>Offset<BR>Claimed</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Unsold</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Aggregate</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Offering</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Amount</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Associated</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">with Fee</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Offset</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Claimed</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Paid</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">with</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Offset</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Source</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="23" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="23" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Newly Registered Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fee&nbsp;Offset</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Claims</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Disc Medicine, Inc.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><FONT STYLE="white-space:nowrap">333-275652</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">November&nbsp;20, 2023</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$25,144.84</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common Stock</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$170,357,981.13</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fee Offset</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sources</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Disc Medicine, Inc.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">333-275652</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">November&nbsp;20, 2023</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$25,144.84</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On November&nbsp;20, 2023, the registrant filed a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-275652)</FONT> (the &#147;Prior Registration Statement&#148;) and on December&nbsp;5, 2023, the registrant filed a prospectus supplement in connection
with its 2023 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offering program (the &#147;2023 ATM Prospectus&#148;). The registrant paid a filing fee in the amount of $59,040.00 to register
shares of its common stock with a maximum aggregate offering price of $400,000,000, which fee was calculated pursuant to Rule 457(o) under the Securities Act. As of the termination of the offering made pursuant to the 2023 ATM Prospectus
$170,357,981.13 of shares of the registrant&#146;s common stock remained unsold. Pursuant to Rule 457(p) under the Securities Act, filing fees in the amount of $25,144.84 relating to the unsold securities are being carried
forward.</P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g912653g03g03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912653g03g03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[1684&AO=&]S:&]P(#,N,  X0DE-! 0
M     &$< 5H  QLE1QP"   "   < E  "')R.#,P.#0S' (% $!-:6-R;W-O
M9G0@5V]R9" M($1I<V,@+2!3+3-!4U(@+2!!=6=U<W0@,C R-"!?1U @1')A
M9G0@."TU+3(T7RYD #A"24T$)0      $'GH'+\-FG<-Q76U0=Z#>@$X0DE-
M!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 6             IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ !@     0 ! &     !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  !%   !M0    8 9P P #, 9P P #,    !
M  $              ;4   !%                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   !%     %)G:'1L;VYG   !M0    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    10    !29VAT;&]N9P   ;4    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     8X0DE-! P     "OD    !    G@   !D
M  '<   N?   "MT &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( !D G@,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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ME\7MO__9 #A"24T$(0      5P    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  (  R #  ,@ Q     0 X0DE-!"(      49-30 J    "  ( 1(  P
M  $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$
M @   !\   !^ 3(  @   !0   "= 3L  @    D   "QAVD !     $   "\
M    Z    &     !    8     %!9&]B92!0:&]T;W-H;W @,C(N," H5VEN
M9&]W<RD ,C R-#HP.#HP-B Q,3HU.3HU-P!R<C@S,#@T,P     #H $  P
M  '__P  H ( !     $   &UH , !     $   !%          8! P #
M 0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
M     0   48" @ $     0              2     $   !(     3A"24T#
M_0      "           _^$!3D5X:68  $U- "H    (  @!$@ #     0 !
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'P   'X!,@ "    %    )T!.P "    "0   +&':0 $     0   +P   #H
M    8     $   !@     4%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S
M*0 R,#(T.C X.C V(#$Q.C4Y.C4W ')R.#,P.#0S      .@ 0 #     ?__
M  "@ @ $     0   ;6@ P $     0   $4         !@$#  ,    !  8
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M5%6AL\+2%18D-U-C0V*"@Z(F1)(G1:/A9(3P_\0 &@$!  (# 0
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M0>KPK>JGMGU/=;9.'P5]4QHSP8_'-65V>:IBU'0/#1():>.(/=(X$N+@>/\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M%30GU(TVKTDM-+#X,A$19E0(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/G5?%IOF'S*IVT?MB/B6?BK8
MU7Q:;YA\RJ=M'[8CXEGXJ&[@W.S^>1RZ(BKG0FSTQVQ6WRAGI!6VTM\@TG@=
MZ152=+]L5L\H9Z05MM+?(-)X'>D5/2:/>?TFT57MKMR=4:IN=(=S=AJCC .>
M2M"JP[7[5+3:FN-:YKA'/5$-)80#P[O7R65O!6VC'C//P< B(JQTH4G[#:]U
M)=:B%N[B>>G:<@G\YPX?6HP4I;#;9+4W.>?=<&P34[_>$];CS^A90\Q5UN/
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M&5C_ )K@5[D\<6N4?5$1#P(B(#\>P/86NY%0IM/V;SU=5/<;5$#///O/,DP
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M/CF^M>91ET2^#9HL2&Y4,WP-7 _YL@*RP01D'(7IXTUR$1$/ B(@"(B (B(
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M5KQR4]3;7<T&ZUPKL2@L=@B(I35A>9'B.-SW9PT9.%@7F\T=IIG35E3!"&D
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MHO1"FJ;><FEW:J%?3T)(SU'FUK4=RL%/$ZUSB(F%[CF-KN((QS"D-1'MZ/\
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M_,6?A2*BW:C)6] I3U+LHJJ)Q-HIZ^I8"[)>YAX#D>04<7&V5ENE,5=3OAD
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M:VEK"T5-;@_\S/Z5(JFS76;I3%X7<JTBL'J+9!;)(G2TM1<9)2[):',QR/\
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MP&%I%W6V>#VOK62/!'Y",\3X5PJI-89VE$NNN,OE!2KL/NCJ6J%("[$]6P$
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M7=3)QFGAG((B*$WAFV68T]XH9FD@QSQO&.\X%6OT'7NN6GHZAY<7&1PRXY/
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MXB3SA3 H>V_'\G2>(D\X4EGE9K]O_,1(#"(BJ'6A=OLGL,=XU12-J6L?3GI
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MWW9VE4.B"C\!;;2+=_4UL:.NH8/WK4KHMGD!FUG91PP:N,')[Z+D]M>(2?\
M0M5IUACLM*PC!#3U8ZROK>/DRH^;^*R*6+H8&1@8W5CWCY,J/F_BKGL<7G,\
M_P!2I.MNVV[>4.\ZTBW>MNVV[>4.\ZTBIOD[2KR1^R"W>C_EIGS'+2+=:/\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M7Q=I6^M]]::P?]LK'N3J=7LU_P &G>XO<2XY)7E;?^[=Y'_VRJ^S*#35Y/\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g912653g18b66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912653g18b66.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@
M;0(U P$B  (1 0,1 ?_$ !P  0$! 0$! 0$!           (!P8%! ," ?_$
M $T0  $# @($!PD-!P,% 0$   $  @,$!081!Q(A,0@305%A@:$4%2(R57&1
MDK$7&$)48H*3E*+!PM'2%B,S4E-RLE;A\"0E0W2S@^/_Q  : 0 " P$!
M           $!0(#!@ !_\0 ,Q$  @(! @0% P,$ 04      0(  Q$$$@4A
M,5$3%$%2814B,D*!H7&1L?#1(S/!X?'_V@ , P$  A$#$0 _ *I1$73H1?#>
M[M0V.V3W"ZU+*:DA&;WO/8!RD\P4Q:2M,%TQ*^6BLKI;=:#FW)IREF'RB-P^
M2.LE$:?3/>?MZ=Y1=J$I'/K-NQEI6PSAATD$E4:ZN9L-/29/+3S.=XK?-GGT
M+(+_ *?<05;G-LU'1VZ+D<X<=)Z3DW[*QU$YJT%5?49/S%=FLL?H<3K:[21C
M"M<3-B&O;GR0OXH>AF2^ 8RQ,'9C$5XS_P#=D_4O!1$BI!T @YL8]3.MHM).
M,*,@PXAKW9<DK^-'VLUV-AT]8DHGM;=:>CN47*=7B9#UMV?960HH-IZGZJ))
M;[%Z,97^!]*^',5/CIFS.H+B[8*:JR&N>9CMSO-L/0N_4 @D',;"M]T'Z59G
MU4&'<35!E$A$='5R'P@[DC>>7/D/5YEFJX?L&^OIVC#3ZW<=MDH%$1*XQA$1
M=.G'Z4L:Q8(PYW<(V3UDT@BIX''(/.\DY;<@.W+G6/\ OAKOY$H/I'KD--F+
MOVJQE/W-)K6VASIZ;(['9'PG]9[ %P">Z;0UBL&P9)B>_5OO(0\IMWOAKOY$
MH/I'I[X:[^1*#Z1ZQ%%?Y*CVRGS5WNF^X?T]7"X7VW4=7:***GJ*B.&21LCL
MV-<X D9\V:H%0'$]T4C)(R6O:0YI'(0KQL]8VXVFBK8_$J8&3#S.:#]Z6\0H
M2K:4&(?HKFLR'.9]:(B6P^<[I!Q&<*81K[RV)LTE.&!D;CD'.<\- SZ\UB?O
MA[GY"HOIG+K^$Y7]SX'HZ-IR=55C<QSM:UQ/;JJ8$XT.EKLJW.,\XKU>H=+-
MJ&;A[X>Y^0J+Z9R>^'N?D*B^F<L/1&>2H]L&\W=[I46BS2\[%^(G6FXT,%%*
M^(O@='(7:[AM+=O1F>HK7%!UEN519[M1W&B=JU%+*V5AZ0<\CT'<K@PY=Z>_
M6*ANE&<X*J(2-&?BY[VGI!S'4E>OTPJ(9!R,8:.\V@JW43T41$OALXG2SC63
M ^'Z>OIZ:.JFFJ1 (Y'%HRU7$G9_:/2LG]\/<_(5%],Y>APJJWP</4+3_6G<
M/5:/Q*?TZT>EK>H,XR3%6JU-B6%5/*;A[X>Y^0J+Z9R>^'N?D*B^F<L/1%>2
MH]L'\W=[I7>C?2!4XIPI=[Y<*&&DAH7/ $;R[6U6![L\_.%F'OA;SY%MWKO_
M #7M6/\ [!P9JZH\62NCDSZ>-DXH?9R4\H73Z:IV<E>0.!^TONU%B*H!YXS-
ML]\+>?(MN]=_YI[X6\^1;=Z[_P UB:(KR5'M@_FK?=-L]\+>?(MN]=_YI[X6
M\^1;=Z[_ ,UB:+O)4>V=YJWW3;/?"WGR+;O7?^:>^%O/D6W>N_\ -8FB[R5'
MMG>:M]TVSWPMY\BV[UW_ )I[X6\^1;=Z[_S6)HN\E1[9WFK?=-L]\+>?(MN]
M=_YK_6<(.]O>UK;);RXG( /?M/I6)+H-'M!WSQQ8J,C-LE9%K#Y(<"[L!46T
ME"@G;TGJZFYB!NEMPEYA890!(6C6 W9\J_M>)BW%-IPI;367JJ;"PYB.,;9)
M3S-;R^P<JG/'.FR^WM\E/8RZT4!V QG.=XZ7_!\S?24FHTME_-1R[QM;J$I_
M+K*.Q!BFQX>9K7JZ4M(<LPQ[_#(Z&CPCU!9[=M/6%Z5SFT,%PKB-SF1B-IZW
M$'L4OS2R3RNEFD?)(XYN>\YDGG)*_@ DY#:4SKX;6/S.8O?7N?Q&)04_"*8'
M'N?#;G#G?69>QA7\0\(K:..PUD.=E;^;%S& M"EYO\<=9>GFTT#LG-:]N<T@
MZ&_!\Y]!6W8<T5X1L3&F*U15DXWS5O[YQZ<CX(Z@%1;Y.OEC)^"?^9;5YJSG
MG G.6+3K8[C((ZBV76G>=YCC$S1ZIS[%I=FO-#>:?CK=,9&<H=&Z-P\[7 $>
MA?93P0T\8CIXHXF#8&L:&@=07Z)?8U;?@N/WAR*X_(Y_:$1%5+(7A8ZOIPUA
M*YW=C&224L6LQC_%<XD!H.720O=7$Z8[%=,28&J[;9&1R5,DC'NC>_5UVM.M
MD"=F>8;OR5E0!<!NF9"PD(2O69![X2^>1[9Z9/U)[X2^>1[9Z9/U+(;K;:VT
MULE'<Z6:EJ8_&CE86D>GDZ5\BT T=!YA8D.JN'ZIM/OA+YY'MGID_4GOA+YY
M'MGID_4L61=Y.CVSO-6^Z;3[X2^>1[9Z9/U)[X2^>1[9Z9/U+%D7>3H]L[S5
MONFW1<(:[ CCK'0N'R9'M_->M0\(B!Q K\/2L'*Z&J#NPM'M4]HO#H:#^F>C
M5W#]4K>P:9\'W9[8Y:R6W2NV!M9'JCU@2T=9"T.FGAJH&34TL<T+QFV2-P<U
MPYP1O4"KK='^/;O@RX,DH9G2T+G S4;W?NY!RY?RNZ1VC8A+N&#&:S":M><X
ML$M%%YV';S28@LE'=+<_7I:E@>W/>.0@](((/F1*""#@QF"",B>BOENMPI;5
M;JBON$S8*6G89))';@!_S<OJ4U\(S&[KC=?V:M\O_1T;LZHM/\2;^7S-]N?,
MKM/0;WVB57W"I-QG%:4<?5N-[P7DOAM4#B*6FSW#^=W.X]F[S\4B+2(BUJ%7
MI$+,7.YNL(BT#1;HSK\;SNJ)'NH[/$[5DJ2W,O/\K!RGIW#IW+K+%K7<QY3U
M$9SM7K,_1658M%^$+/ UD5EIJIX&V6L:)W.//X6P=0"^BZ:.<(W*%T=1A^WQ
MYCQJ>(0N'6S(I?\ 4Z\]#B&_3WQU$BU%I6F#1G)@F>*MH)9*BS5#]1KG^/"_
M:=5Q&_, Y'H/7FJ/KL6U=R]($Z-6VUH1I+7 M)!&T$<B(K)"67H@Q.[%>!Z*
MLJ'ZU;#G35)YWMRV]8+3UKLU/?!6N+A4W^VN=FQS(ZAHYB"6N]K?0J$69U58
MKM91TC_3/XE8)A9SIUQ=^S&#I8*:35N-QSIX<CM:W+PW]0.7G<%HKG-8TN>0
MUH&9).0 4:Z6L6'%V,:JKB>300?N*4<G%M)\+YQS/6.96:&CQ;,GH)#5W>&F
M!U,XQ$1:*(X1$73H5D:%;AWQT96.0G-T41IST:CBT=@"C=4UP7KAQ^#[E0N.
M;J6LUP.9KVC+M:Y+^)+FK/8PW0-BS'<39$1$ACF3IPJ*_7O%BMX/\&"2<C^]
MVJ/\"L,6C<(*O[MTFW!@.;:6.* =3=8]KBLY6ETB[:5$0:EMUK&$1$3*(5!<
M&+%.M'6X9JI-K<ZJES/)\-H['9=+E/J]3"UZJ,.XAH+M2?Q:64/U<\M9NYS3
MT$9CK5&HJ\:LI+J+/"<-+J1?+:J^GNELI:^C?KTU3$V6-W.TC,+ZEF",<C-
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8A=BB#:\LI3'+.84M(5MV>>,0B(J9;/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g912653g96b12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912653g96b12.jpg
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MK.+WEJCA+:W5-PES7 (B+TP"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M-L'":U3-M6:YTEXME/7VZ9LU+.W68\>@\A&XA?8LQZ%\=.PU=Q;KC*?R16/
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M686;+RZUJX/X<? LE%\MMN-%<Z85%MJX*J ^'#('CS+ZEM(#33T81$0\"(B
M(B( B*+8EQ_AO#KG1W"Y1NJ&[X(/;) >0@;NO)>.27%F==4[7NP6K]Q*45+7
M+3U1,<1;;)43-XG3S"/S .]*Y1T]UVMLL=-J\G9W?@M3R*UUEA'8^9):[GU7
MY+^14E;M/=.YP%QL4L;>-T$X>?(0/2I]AK2/AG$#VQ4EQ;!4NV""I'8W$\@S
MV$]!*RC;"7)FF[9V32M9P>GS\"7JJ.$D/_!%">2X,'_YR*UU5/"1]XU%_P#8
MQ_RY5Y=ZMGNS/:J^\S>B(JL[\*_.#)[G7_ZV'T.5!J_.#)[G7_ZV'T.6_&]8
MBJVS['/X>)=2(BLCAR/8QP?:,6T8ANT!,C![5/&=62/H/)S',*HKCH&KFS'\
MFWFFDA)V=L1N8X>3//S*:^S1A/CDKA_T_P#NO+=,^$COFK!TTY_%1Y^9GQ;+
MG&_<L9;M<7IV::D1M&@:3LS77B],[$-[*6(YG]IV[R%7#AK#]MPW;6T-HIFP
M0C:X[W//QG'>2H;[,V$?\15_NY7UV72MAJ\W6EMU%)5FIJ'B./6AR&9Y3FO8
M>:AT6897[AD1_K1>B]VB)XB(MY4A$1 $1$ 116_Z0L,6-SF5MUA=.W88H/;7
M@\A#<\NO)0BXZ>+3$XBWVFMJ,N.5[8@?)K+7*V$>;)E6!DW+6$'X>)<**AGZ
M?)R[N,/Q <]43_2OVIM/O= 5.'MG+'5_<6+']17VDA[&S/X?5?DO-%5UJTVX
M:JG!M;%74+CO<^,/:.MI)\RGMDQ%:+Y'KVBXTU7D,RV-XUATMWCK"SC9&7)D
M.[$OI]9!HZB(BS(X1$0',Q%8;;B*W.H;O2LJ(#M&>QS#RM.\%4]>M SC,YUE
MO#1&3LCJX]H_:;O\BG-ZTJX;LUVJ;=725;:FG?J2:L.8SYCFOC]F;"/^(J_W
M<K1/S4^DRVQ?W#'6M,7H_=JB$6[0+7.F'Y1O--'%Q]@C<\GRY9*V\&8,L^$:
M5T=J@)F>,I*B4ZTC^D\0YAD%&SIGPB!LGK#T4Y7J--&$R0 ^N))R_5_]UY#S
M,.*9GD/:62MVR+T[--"R40', CC12"F"+@8PQ;;,)4M/47=TPCG>8V=B9K'/
M+-1<:9\(D?IZP?\ 3E8.R,7HV2:\2^V.]"#:[BQT5<>S-A'_ !%7^[E/9FPC
M_P"O5_NY7GG8=IG^WY7_ ,W\BQT7#PCBBW8KMTM;:'2F".4PN[(S5.L #NZ"
M%W%FFFM419PE7)QDM&@BB&)](V&L.O?%65XFJF[#3TP[(\'D.6P'I(4!K]/=
M.UQ%OL4LC>)T]0&'R 'TK"5L(\V2Z=G9-RUA!Z?+Q+M14+'I\J@[VRP0EO(V
MI(/JKO6C3I9:AS6W.WUE$3X3")FCIW'S+%7UOK-L]D9<%JX?)IEN(N58,16G
M$$!FL]?!5- S<UCNZ;TM.T=8756U-/BBOE&4'NR6C"(B],0B(@"(B (BX]^Q
M-9; S6O%RIJ4Y9ACG9O/0T;3Y%XVEQ9E&$IO=BM6=A%5%UTY8?IG.;;Z.NK2
M-SM41L/63GYE':C3Y.2>U[!$T?/JB[T-"U.^M=9/ALG+FM5#YZ(OE%0<6GNK
M#O;K# X?-J"W^DKMVW3O:)7 7&U5M-GQQ/;*!Y=4HLBM]9[/9&7'CN?5%PHH
MSA['>&[^YK+==8#.[=#*>QO)Y '99]6:DRVII\40+*YUO=FM'[PB(O3 (B(
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MRDH)RD]$CF1L=(]K(VN<]QR#6C,DJ56_1UBVX1"2GL54&':#-JQ>9Y"T?@7
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MRX8QG,H)I+7&[*2I<W/6/Q6#C/F'F6BL*X'L.&8FBVT$9J -M3*->5W[1W=
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MHM'N![?@VW=CI@)JZ4#L]4X=T\\@Y&\WE4G&C+>U7(HMMWT*KS4^,NKW>_\
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M^DRNR-OUQ6E,=7[^7^_(JO &ANBM3HZW$CHZ^L&3FTX'M,9Y\^_/3LYBK;:
MUH#0 !L '$B*7"$8+2)SF1E6Y,M^UZA$19D<(B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( N'B2YS6$-N3V/FM;>YJVL&;H6
M\4H'&!X0Y-HW'/N+P]C9&.8]H<QPR+2,P1R+QHSA)1>LEJC\Z2IAK*:*HI96
M302M#F2,.;7 \8*_54O>Y+KHFO!J;;&^MPA5R9NIG']6>=X:?!YN([CMVJSL
M*XGM6** 55HJ6R@=_&=DD9Y'-XO1R+"-B;W7S)%^)*N*MAQ@^O[/L9VD1%L(
M@1$0!$1 $1$ 1$0!$1 %R\27ZWX<M4MPNLXB@9L WN>[B:T<9*X>/-(%HPA3
MN;42"IN)&<=)&[NCR%Q\$<YZ@5F?&&*KGBRYFKNLV8&8BA9LCB'(T??O*T6W
MJ'!<RVV?LJS*>_/A#Q[OR?7I!QG78QNW;%3G%219MIZ8',1MY3RN/&5%D15S
M;D]6=G57&J*A!:)!$7U6JWU5UN$%#;X7SU4[M1C&C:3^'.O.9FVDM6=3 ^&:
MK%>(*>VT@+6$ZTTN68BC&]Q^[G(6O;1;J:T6RFH*",1TU.P1L;S#EY^-1W1K
M@RFP;8Q3MU9*^;)]5.!WSOBCYHXNL\:EJLJ*O-K5\SB-JY_ZNS=AT5R]_O"(
MBWE4$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
